Raras
Buscar doenças, sintomas, genes...
Doença do metabolismo dos aminoácidos ou proteínas
ORPHA:79062DOENÇA RARA
neuro

Doença rara do metabolismo de aminoácidos/proteínas, com manifestações neurológicas (anartria, padrão respiratório anormal, hipoplasia cerebelar), cardíacas e hematológicas (anemia hemolítica, hipercoagulabilidade). Pode apresentar aumento de ferro sérico e ácido malônico na urina.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋
Informacoes curadas por IA — podem conter imprecisoes

Doença rara do metabolismo de aminoácidos/proteínas, com manifestações neurológicas (anartria, padrão respiratório anormal, hipoplasia cerebelar), cardíacas e hematológicas (anemia hemolítica, hipercoagulabilidade). Pode apresentar aumento de ferro sérico e ácido malônico na urina.

🏥
SUS: Sem cobertura SUSScore: 20%
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🧠
Neurológico
212 sintomas
👁️
Olhos
143 sintomas
🦴
Ossos e articulações
133 sintomas
🫘
Rins
127 sintomas
🧬
Pele e cabelo
87 sintomas
😀
Face
76 sintomas

+ 1075 sintomas em outras categorias

Características mais comuns

Anartria
Hemorragia uterina
Padrão anormal de respiração
Função ventricular cardíaca anormal
Hipercoagulabilidade
Anisocitose
2283sintomas
Sem dados (2283)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 2283 características clínicas mais associadas, ordenadas por frequência.

AnartriaAnarthria
Hemorragia uterinaHP:6001352
Padrão anormal de respiraçãoAbnormal pattern of respiration
Função ventricular cardíaca anormalAbnormal cardiac ventricular function
HipercoagulabilidadeHypercoagulability

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa7
Últimos 10 anos200publicações
Pico202538 papers
Linha do tempo
20202019Hoje · 2026📈 2025Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

90 genes identificados com associação a esta condição.

BLOC1S3Biogenesis of lysosome-related organelles complex 1 subunit 3Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Component of the BLOC-1 complex, a complex that is required for normal biogenesis of lysosome-related organelles (LRO), such as platelet dense granules and melanosomes. In concert with the AP-3 complex, the BLOC-1 complex is required to target membrane protein cargos into vesicles assembled at cell bodies for delivery into neurites and nerve terminals. The BLOC-1 complex, in association with SNARE proteins, is also proposed to be involved in neurite extension. Plays a role in intracellular vesic

LOCALIZAÇÃO

Cytoplasm

VIAS BIOLÓGICAS (1)
Golgi Associated Vesicle Biogenesis
MECANISMO DE DOENÇA

Hermansky-Pudlak syndrome 8

A form of Hermansky-Pudlak syndrome, a genetically heterogeneous autosomal recessive disorder characterized by oculocutaneous albinism, bleeding due to platelet storage pool deficiency, and lysosomal storage defects. This syndrome results from defects of diverse cytoplasmic organelles including melanosomes, platelet dense granules and lysosomes. Ceroid storage in the lungs is associated with pulmonary fibrosis, a common cause of premature death in individuals with HPS.

OUTRAS DOENÇAS (2)
Hermansky-Pudlak syndrome 8Hermansky-Pudlak syndrome 7
HGNC:20914UniProt:Q6QNY0
SLC3A1Amino acid transporter heavy chain SLC3A1Candidate gene tested inTolerante
FUNÇÃO

Acts as a chaperone that facilitates biogenesis and trafficking of functional transporter heteromers to the plasma membrane (By similarity) (PubMed:10588648, PubMed:11318953, PubMed:16609684, PubMed:16825196, PubMed:32494597, PubMed:32817565, PubMed:7686906, PubMed:8486766, PubMed:8663184, PubMed:8663357). Associates with SLC7A9 to form a functional transporter complex that mediates the electrogenic exchange between cationic amino acids and neutral amino acids, with a stoichiometry of 1:1. SLC7A

LOCALIZAÇÃO

Cell membraneApical cell membrane

VIAS BIOLÓGICAS (2)
Amino acid transport across the plasma membraneDefective SLC7A9 causes cystinuria (CSNU)
MECANISMO DE DOENÇA

Cystinuria

An autosomal disorder characterized by impaired epithelial cell transport of cystine and dibasic amino acids (lysine, ornithine, and arginine) in the proximal renal tubule and gastrointestinal tract. The impaired renal reabsorption of cystine and its low solubility causes the formation of calculi in the urinary tract, resulting in obstructive uropathy, pyelonephritis, and, rarely, renal failure.

EXPRESSÃO TECIDUAL(Tecido-específico)
Rim - Córtex
29.4 TPM
Rim - Medula
18.3 TPM
Intestino delgado
14.8 TPM
Pâncreas
13.7 TPM
Cólon transverso
2.2 TPM
OUTRAS DOENÇAS (5)
cystinuriacystinuria type Ahypotonia-cystinuria syndrome2p21 microdeletion syndrome
HGNC:11025UniProt:Q07837
GCH1GTP cyclohydrolase 1Candidate gene tested inAltamente restrito
FUNÇÃO

Positively regulates nitric oxide synthesis in umbilical vein endothelial cells (HUVECs). May be involved in dopamine synthesis. May modify pain sensitivity and persistence. Isoform GCH-1 is the functional enzyme, the potential function of the enzymatically inactive isoforms remains unknown

LOCALIZAÇÃO

CytoplasmNucleus

VIAS BIOLÓGICAS (1)
Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
MECANISMO DE DOENÇA

Hyperphenylalaninemia, BH4-deficient, B

A disease characterized by malignant hyperphenylalaninemia due to tetrahydrobiopterin deficiency, and defective neurotransmission due to depletion of the neurotransmitters dopamine and serotonin. The principal symptoms include: psychomotor retardation, tonicity disorders, convulsions, drowsiness, irritability, abnormal movements, hyperthermia, hypersalivation, and difficulty swallowing. Some patients may present a phenotype of intermediate severity between severe hyperphenylalaninemia and mild dystonia. In this intermediate phenotype, there is marked motor delay, but no intellectual disability and only minimal, if any, hyperphenylalaninemia.

EXPRESSÃO TECIDUAL(Ubíquo)
Fígado
49.0 TPM
Linfócitos
35.0 TPM
Pulmão
24.3 TPM
Baço
16.3 TPM
Intestino delgado
15.3 TPM
OUTRAS DOENÇAS (3)
dystonia 5GTP cyclohydrolase I deficiency with hyperphenylalaninemiaautosomal dominant dopa-responsive dystonia
HGNC:4193UniProt:P30793
SLC6A19Sodium-dependent neutral amino acid transporter B(0)AT1Candidate gene tested inTolerante
FUNÇÃO

Transporter that mediates resorption of neutral amino acids across the apical membrane of renal and intestinal epithelial cells (PubMed:15286787, PubMed:15286788, PubMed:18424768, PubMed:18484095, PubMed:19185582, PubMed:26240152). This uptake is sodium-dependent and chloride-independent (PubMed:15286787, PubMed:15286788, PubMed:19185582). Requires CLTRN in kidney or ACE2 in intestine for cell surface expression and amino acid transporter activity (PubMed:18424768, PubMed:19185582)

LOCALIZAÇÃO

Cell membraneApical cell membrane

VIAS BIOLÓGICAS (2)
SLC-mediated transport of neurotransmittersAmino acid transport across the plasma membrane
MECANISMO DE DOENÇA

Hartnup disorder

Autosomal recessive abnormality of renal and gastrointestinal neutral amino acid transport noted for its clinical variability. First described in 1956, HND is characterized by increases in the urinary and intestinal excretion of neutral amino acids. Individuals with typical Hartnup aminoaciduria may be asymptomatic, some develop a photosensitive pellagra-like rash, attacks of cerebellar ataxia and other neurological or psychiatric features. Although the definition of HND was originally based on clinical and biochemical abnormalities, its marked clinical heterogeneity has led to it being known as a disorder with a consistent pathognomonic neutral hyperaminoaciduria.

EXPRESSÃO TECIDUAL(Tecido-específico)
Intestino delgado
70.7 TPM
Rim - Córtex
20.2 TPM
Rim - Medula
5.5 TPM
Cólon transverso
0.6 TPM
Fígado
0.5 TPM
OUTRAS DOENÇAS (2)
Hartnup diseaseiminoglycinuria
HGNC:27960UniProt:Q695T7
MTRRMethionine synthase reductaseCandidate gene tested inTolerante
FUNÇÃO

Key enzyme in methionine and folate homeostasis responsible for the reactivation of methionine synthase (MTR/MS) activity by catalyzing the reductive methylation of MTR-bound cob(II)alamin (PubMed:17892308). Cobalamin (vitamin B12) forms a complex with MTR to serve as an intermediary in methyl transfer reactions that cycles between MTR-bound methylcob(III)alamin and MTR bound-cob(I)alamin forms, and occasional oxidative escape of the cob(I)alamin intermediate during the catalytic cycle leads to

LOCALIZAÇÃO

Cytoplasm

VIAS BIOLÓGICAS (4)
Cobalamin (Cbl) metabolismMethylationSulfur amino acid metabolismDefective MTR causes HMAG
MECANISMO DE DOENÇA

Homocystinuria-megaloblastic anemia, cblE type

An autosomal recessive inborn error of metabolism resulting from defects in the cobalamin-dependent pathway that converts homocysteine to methionine. It causes delayed psychomotor development, megaloblastic anemia, homocystinuria, and hypomethioninemia. Cells from patients with HMAE fail to incorporate methyltetrahydrofolate into methionine in whole cells, but cell extracts show normal methionine synthase activity in the presence of a reducing agent.

EXPRESSÃO TECIDUAL(Ubíquo)
Pulmão
23.0 TPM
Fibroblastos
22.4 TPM
Linfócitos
22.3 TPM
Útero
21.2 TPM
Nervo tibial
21.0 TPM
OUTRAS DOENÇAS (2)
methylcobalamin deficiency type cblEneural tube defects, folate-sensitive
HGNC:7473UniProt:Q9UBK8
MCCC2Methylcrotonoyl-CoA carboxylase beta chain, mitochondrialCandidate gene tested inTolerante
FUNÇÃO

Carboxyltransferase subunit of the 3-methylcrotonyl-CoA carboxylase, an enzyme that catalyzes the conversion of 3-methylcrotonyl-CoA to 3-methylglutaconyl-CoA, a critical step for leucine and isovaleric acid catabolism

LOCALIZAÇÃO

Mitochondrion matrix

VIAS BIOLÓGICAS (3)
Branched-chain amino acid catabolismBiotin transport and metabolism3-Methylcrotonyl-CoA carboxylase deficiency
MECANISMO DE DOENÇA

3-methylcrotonoyl-CoA carboxylase 2 deficiency

An autosomal recessive disorder of leucine catabolism. The phenotype is variable, ranging from neonatal onset with severe neurological involvement to asymptomatic adults. There is a characteristic organic aciduria with massive excretion of 3-hydroxyisovaleric acid and 3-methylcrotonylglycine, usually in combination with a severe secondary carnitine deficiency.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
63.1 TPM
Glândula adrenal
47.8 TPM
Tireoide
39.6 TPM
Próstata
37.3 TPM
Fígado
35.7 TPM
OUTRAS DOENÇAS (2)
3-methylcrotonyl-CoA carboxylase 2 deficiency3-methylcrotonyl-CoA carboxylase deficiency
HGNC:6937UniProt:Q9HCC0
PRCDPhotoreceptor disk component PRCDCandidate gene tested inTolerante
FUNÇÃO

Involved in vision

LOCALIZAÇÃO

Cell projection, cilium, photoreceptor outer segmentMembraneEndoplasmic reticulumGolgi apparatus

MECANISMO DE DOENÇA

Retinitis pigmentosa 36

A retinal dystrophy belonging to the group of pigmentary retinopathies. Retinitis pigmentosa is characterized by retinal pigment deposits visible on fundus examination and primary loss of rod photoreceptor cells followed by secondary loss of cone photoreceptors. Patients typically have night vision blindness and loss of midperipheral visual field. As their condition progresses, they lose their far peripheral visual field and eventually central vision as well.

EXPRESSÃO TECIDUAL(Ubíquo)
Cerebelo
21.0 TPM
Cérebro - Hemisfério cerebelar
20.5 TPM
Brain Spinal cord cervical c-1
8.0 TPM
Cervix Endocervix
6.6 TPM
Cervix Ectocervix
6.6 TPM
OUTRAS DOENÇAS (2)
retinitis pigmentosa 36retinitis pigmentosa
HGNC:32528UniProt:Q00LT1
CERKLCeramide kinase-like proteinCandidate gene tested inTolerante
FUNÇÃO

Has no detectable ceramide-kinase activity. Overexpression of CERKL protects cells from apoptosis in oxidative stress conditions

LOCALIZAÇÃO

CytoplasmNucleus, nucleolusGolgi apparatus, trans-Golgi networkEndoplasmic reticulum

MECANISMO DE DOENÇA

Retinitis pigmentosa 26

A retinal dystrophy belonging to the group of pigmentary retinopathies. Retinitis pigmentosa is characterized by retinal pigment deposits visible on fundus examination and primary loss of rod photoreceptor cells followed by secondary loss of cone photoreceptors. Patients typically have night vision blindness and loss of midperipheral visual field. As their condition progresses, they lose their far peripheral visual field and eventually central vision as well.

OUTRAS DOENÇAS (2)
retinitis pigmentosa 26retinitis pigmentosa
HGNC:21699UniProt:Q49MI3
MAKSerine/threonine-protein kinase MAKCandidate gene tested inTolerante
FUNÇÃO

Essential for the regulation of ciliary length and required for the long-term survival of photoreceptors (By similarity). Phosphorylates FZR1 in a cell cycle-dependent manner. Plays a role in the transcriptional coactivation of AR. Could play an important function in spermatogenesis. May play a role in chromosomal stability in prostate cancer cells

LOCALIZAÇÃO

NucleusCytoplasm, cytoskeleton, microtubule organizing center, centrosomeCytoplasm, cytoskeleton, spindleMidbodyCell projection, cilium, photoreceptor outer segmentPhotoreceptor inner segment

VIAS BIOLÓGICAS (2)
Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6
MECANISMO DE DOENÇA

Retinitis pigmentosa 62

A retinal dystrophy belonging to the group of pigmentary retinopathies. Retinitis pigmentosa is characterized by retinal pigment deposits visible on fundus examination and primary loss of rod photoreceptor cells followed by secondary loss of cone photoreceptors. Patients typically have night vision blindness and loss of midperipheral visual field. As their condition progresses, they lose their far peripheral visual field and eventually central vision as well.

EXPRESSÃO TECIDUAL(Tecido-específico)
Testículo
15.1 TPM
Sangue
2.7 TPM
Pituitária
1.8 TPM
Fallopian Tube
1.3 TPM
Baço
1.3 TPM
OUTRAS DOENÇAS (2)
retinitis pigmentosa 62retinitis pigmentosa
HGNC:6816UniProt:P20794
SNRNP200U5 small nuclear ribonucleoprotein 200 kDa helicaseCandidate gene tested inAltamente restrito
FUNÇÃO

Catalyzes the ATP-dependent unwinding of U4/U6 RNA duplices, an essential step in the assembly of a catalytically active spliceosome (PubMed:35241646). Plays a role in pre-mRNA splicing as a core component of precatalytic, catalytic and postcatalytic spliceosomal complexes (PubMed:28502770, PubMed:28781166, PubMed:29301961, PubMed:29360106, PubMed:29361316, PubMed:30315277, PubMed:30705154, PubMed:30728453). As a component of the minor spliceosome, involved in the splicing of U12-type introns in

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (3)
mRNA Splicing - Major PathwayDengue Virus-Host InteractionsmRNA Splicing - Minor Pathway
MECANISMO DE DOENÇA

Retinitis pigmentosa 33

A retinal dystrophy belonging to the group of pigmentary retinopathies. Retinitis pigmentosa is characterized by retinal pigment deposits visible on fundus examination and primary loss of rod photoreceptor cells followed by secondary loss of cone photoreceptors. Patients typically have night vision blindness and loss of midperipheral visual field. As their condition progresses, they lose their far peripheral visual field and eventually central vision as well.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
153.3 TPM
Ovário
132.5 TPM
Útero
119.1 TPM
Cervix Endocervix
112.7 TPM
Cérebro - Hemisfério cerebelar
109.0 TPM
OUTRAS DOENÇAS (2)
retinitis pigmentosa 33retinitis pigmentosa
HGNC:30859UniProt:O75643
BBS1BBSome complex member BBS1Candidate gene tested inTolerante
FUNÇÃO

The BBSome complex is thought to function as a coat complex required for sorting of specific membrane proteins to the primary cilia. The BBSome complex is required for ciliogenesis but is dispensable for centriolar satellite function. This ciliogenic function is mediated in part by the Rab8 GDP/GTP exchange factor, which localizes to the basal body and contacts the BBSome. Rab8(GTP) enters the primary cilium and promotes extension of the ciliary membrane. Firstly the BBSome associates with the c

LOCALIZAÇÃO

Cell projection, cilium membraneCytoplasmCytoplasm, cytoskeleton, microtubule organizing center, centrosome, centriolar satellite

VIAS BIOLÓGICAS (1)
BBSome-mediated cargo-targeting to cilium
OUTRAS DOENÇAS (3)
Bardet-Biedl syndrome 1retinitis pigmentosaBardet-Biedl syndrome
HGNC:966UniProt:Q8NFJ9
ROM1Rod outer segment membrane protein 1Candidate gene tested inTolerante
FUNÇÃO

Plays a role in rod outer segment (ROS) morphogenesis (By similarity). May play a role with PRPH2 in the maintenance of the structure of ROS curved disks (By similarity). Plays a role in the organization of the ROS and maintenance of ROS disk diameter (By similarity). Involved in the maintenance of the retina outer nuclear layer (By similarity)

LOCALIZAÇÃO

Photoreceptor inner segment membranePhotoreceptor outer segment membrane

MECANISMO DE DOENÇA

Retinitis pigmentosa 7

A retinal dystrophy belonging to the group of pigmentary retinopathies. Retinitis pigmentosa is characterized by retinal pigment deposits visible on fundus examination and primary loss of rod photoreceptor cells followed by secondary loss of cone photoreceptors. Patients typically have night vision blindness and loss of midperipheral visual field. As their condition progresses, they lose their far peripheral visual field and eventually central vision as well.

EXPRESSÃO TECIDUAL(Ubíquo)
Brain Spinal cord cervical c-1
56.0 TPM
Substância negra
34.4 TPM
Cérebro - Amígdala
24.2 TPM
Hipocampo
23.2 TPM
Cérebro - Hemisfério cerebelar
22.3 TPM
OUTRAS DOENÇAS (2)
retinitis pigmentosa 7retinitis pigmentosa
HGNC:10254UniProt:Q03395
ETFDHElectron transfer flavoprotein-ubiquinone oxidoreductase, mitochondrialCandidate gene tested inTolerante
FUNÇÃO

Accepts electrons from ETF and reduces ubiquinone

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (1)
Respiratory electron transport
MECANISMO DE DOENÇA

Glutaric aciduria 2C

An autosomal recessively inherited disorder of fatty acid, amino acid, and choline metabolism. It is characterized by multiple acyl-CoA dehydrogenase deficiencies resulting in large excretion not only of glutaric acid, but also of lactic, ethylmalonic, butyric, isobutyric, 2-methyl-butyric, and isovaleric acids.

EXPRESSÃO TECIDUAL(Ubíquo)
Coração - Ventrículo esquerdo
51.2 TPM
Fígado
43.3 TPM
Glândula adrenal
41.9 TPM
Músculo esquelético
41.7 TPM
Coração - Átrio
38.5 TPM
OUTRAS DOENÇAS (3)
multiple acyl-CoA dehydrogenase deficiencymultiple acyl-CoA dehydrogenase deficiency, severe neonatal typemultiple acyl-CoA dehydrogenase deficiency, mild type
HGNC:3483UniProt:Q16134
ETFAElectron transfer flavoprotein subunit alpha, mitochondrialCandidate gene tested inTolerante
FUNÇÃO

Heterodimeric electron transfer flavoprotein that accepts electrons from several mitochondrial dehydrogenases, including acyl-CoA dehydrogenases, glutaryl-CoA and sarcosine dehydrogenase (PubMed:10356313, PubMed:15159392, PubMed:15975918, PubMed:27499296, PubMed:9334218). It transfers the electrons to the main mitochondrial respiratory chain via ETF-ubiquinone oxidoreductase (ETF dehydrogenase) (PubMed:9334218). Required for normal mitochondrial fatty acid oxidation and normal amino acid metabol

LOCALIZAÇÃO

Mitochondrion matrix

VIAS BIOLÓGICAS (1)
Respiratory electron transport
MECANISMO DE DOENÇA

Glutaric aciduria 2A

An autosomal recessively inherited disorder of fatty acid, amino acid, and choline metabolism. It is characterized by multiple acyl-CoA dehydrogenase deficiencies resulting in large excretion not only of glutaric acid, but also of lactic, ethylmalonic, butyric, isobutyric, 2-methyl-butyric, and isovaleric acids.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
144.9 TPM
Músculo esquelético
109.5 TPM
Glândula adrenal
101.8 TPM
Coração - Ventrículo esquerdo
98.5 TPM
Fígado
90.9 TPM
OUTRAS DOENÇAS (3)
multiple acyl-CoA dehydrogenase deficiencymultiple acyl-CoA dehydrogenase deficiency, mild typemultiple acyl-CoA dehydrogenase deficiency, severe neonatal type
HGNC:3481UniProt:P13804
GPHNGephyrinCandidate gene tested inAltamente restrito
FUNÇÃO

Microtubule-associated protein involved in membrane protein-cytoskeleton interactions. It is thought to anchor the inhibitory glycine receptor (GLYR) to subsynaptic microtubules (By similarity). Acts as a major instructive molecule at inhibitory synapses, where it also clusters GABA type A receptors (PubMed:25025157, PubMed:26613940) Also has a catalytic activity and catalyzes two steps in the biosynthesis of the molybdenum cofactor. In the first step, molybdopterin is adenylated. Subsequently,

LOCALIZAÇÃO

Postsynaptic cell membraneCell membraneCytoplasm, cytosolCytoplasm, cytoskeletonCell projection, dendritePostsynaptic density

VIAS BIOLÓGICAS (1)
Molybdenum cofactor biosynthesis
MECANISMO DE DOENÇA

Molybdenum cofactor deficiency C

A form of molybdenum cofactor deficiency, an autosomal recessive metabolic disorder leading to the pleiotropic loss of molybdoenzyme activities. It is clinically characterized by onset in infancy of poor feeding, intractable seizures, severe psychomotor retardation, and death in early childhood in most patients.

EXPRESSÃO TECIDUAL(Ubíquo)
Cérebro - Hemisfério cerebelar
45.3 TPM
Cerebelo
39.3 TPM
Linfócitos
28.2 TPM
Brain Frontal Cortex BA9
18.1 TPM
Córtex cerebral
15.4 TPM
OUTRAS DOENÇAS (2)
sulfite oxidase deficiency due to molybdenum cofactor deficiency type Chereditary hyperekplexia
HGNC:15465UniProt:Q9NQX3
MECREnoyl-[acyl-carrier-protein] reductase, mitochondrialCandidate gene tested inTolerante
FUNÇÃO

Catalyzes the NADPH-dependent reduction of trans-2-enoyl thioesters in mitochondrial fatty acid synthesis (fatty acid synthesis type II). Fatty acid chain elongation in mitochondria uses acyl carrier protein (ACP) as an acyl group carrier, but the enzyme accepts both ACP and CoA thioesters as substrates in vitro. Displays a preference for medium-chain over short- and long-chain substrates (PubMed:12654921, PubMed:18479707, PubMed:27817865). May provide the octanoyl chain used for lipoic acid bio

LOCALIZAÇÃO

MitochondrionCytoplasmNucleus

VIAS BIOLÓGICAS (1)
Beta oxidation of decanoyl-CoA to octanoyl-CoA-CoA
MECANISMO DE DOENÇA

Dystonia, childhood-onset, with optic atrophy and basal ganglia abnormalities

An autosomal recessive neurologic disorder characterized by childhood-onset dystonia, basal ganglia degeneration and optic atrophy with decreased visual acuity. Dystonia is defined by the presence of sustained involuntary muscle contraction, often leading to abnormal postures. DYTOABG severity is variable, and some patients lose independent ambulation.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
16.3 TPM
Nervo tibial
15.9 TPM
Útero
15.8 TPM
Cervix Endocervix
15.2 TPM
Cervix Ectocervix
14.8 TPM
OUTRAS DOENÇAS (3)
dystonia, childhood-onset, with optic atrophy and basal ganglia abnormalitiesoptic atrophy 16obsolete autosomal recessive optic atrophy
HGNC:19691UniProt:Q9BV79
MOCS1Molybdenum cofactor biosynthesis protein 1Candidate gene tested inTolerante
FUNÇÃO

Isoform MOCS1A and isoform MOCS1B probably form a complex that catalyzes the conversion of 5'-GTP to cyclic pyranopterin monophosphate (cPMP) (PubMed:11891227, PubMed:23627491, PubMed:29368224, PubMed:31996372). MOCS1A catalyzes the cyclization of GTP to (8S)-3',8-cyclo-7,8-dihydroguanosine 5'-triphosphate and MOCS1B catalyzes the subsequent conversion of (8S)-3',8-cyclo-7,8-dihydroguanosine 5'-triphosphate to cPMP (PubMed:11891227, PubMed:23627491, PubMed:29368224, PubMed:31996372) Has very wea

LOCALIZAÇÃO

Mitochondrion matrixCytoplasm, cytosolCytoplasm

VIAS BIOLÓGICAS (1)
Molybdenum cofactor biosynthesis
MECANISMO DE DOENÇA

Molybdenum cofactor deficiency A

An autosomal recessive metabolic disorder leading to the pleiotropic loss of molybdoenzyme activities. It is clinically characterized by onset in infancy of poor feeding, intractable seizures, severe psychomotor retardation, and death in early childhood in most patients.

EXPRESSÃO TECIDUAL(Ubíquo)
Tecido adiposo
65.8 TPM
Nervo tibial
53.7 TPM
Artéria tibial
52.5 TPM
Mama
50.1 TPM
Adipose Visceral Omentum
47.9 TPM
OUTRAS DOENÇAS (1)
sulfite oxidase deficiency due to molybdenum cofactor deficiency type A
HGNC:7190UniProt:Q9NZB8
MMADHCCobalamin trafficking protein CblDCandidate gene tested inTolerante
FUNÇÃO

Involved in cobalamin metabolism and trafficking (PubMed:18385497, PubMed:23415655, PubMed:24722857, PubMed:26364851). Plays a role in regulating the biosynthesis and the proportion of two coenzymes, methylcob(III)alamin (MeCbl) and 5'-deoxyadenosylcobalamin (AdoCbl) (PubMed:18385497, PubMed:23415655, PubMed:24722857). Promotes oxidation of cob(II)alamin bound to MMACHC (PubMed:26364851). The processing of cobalamin in the cytosol occurs in a multiprotein complex composed of at least MMACHC, MMA

LOCALIZAÇÃO

CytoplasmMitochondrion

VIAS BIOLÓGICAS (1)
Cobalamin (Cbl) metabolism
MECANISMO DE DOENÇA

Methylmalonic aciduria and homocystinuria, cblD type

An autosomal recessive disorder of cobalamin metabolism characterized by decreased levels of the coenzymes adenosylcobalamin (AdoCbl) and methylcobalamin (MeCbl). Clinical features include developmental delay, hyotonia, intellectual disability, seizures, and megaloblastic anemia. Laboratory studies show methylmalonic aciduria and homocystinuria.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
157.4 TPM
Fibroblastos
145.1 TPM
Artéria tibial
139.0 TPM
Músculo esquelético
127.1 TPM
Aorta
115.0 TPM
OUTRAS DOENÇAS (5)
methylmalonic aciduria and homocystinuria type cblDhomocystinuria-megaloblastic anemia cblD typeisolated methylmalonic aciduria cblD typemethylcobalamin deficiency type cblDv1
HGNC:25221UniProt:Q9H3L0
ACAT1Sterol O-acyltransferase 1Candidate gene tested inTolerante
FUNÇÃO

Catalyzes the formation of fatty acid-cholesterol esters, which are less soluble in membranes than cholesterol (PubMed:16154994, PubMed:16647063, PubMed:32433613, PubMed:32433614, PubMed:32944968, PubMed:9020103). Plays a role in lipoprotein assembly and dietary cholesterol absorption (PubMed:16154994, PubMed:9020103). Preferentially utilizes oleoyl-CoA ((9Z)-octadecenoyl-CoA) as a substrate: shows a higher activity towards an acyl-CoA substrate with a double bond at the delta-9 position (9Z) th

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (5)
Branched-chain amino acid catabolismUtilization of Ketone BodiesSynthesis of Ketone BodiesMaturation of TCA enzymes and regulation of TCA cycleMitochondrial protein degradation
VIAS REACTOME (1)
OUTRAS DOENÇAS (1)
beta-ketothiolase deficiency
HGNC:93UniProt:P35610
MYO5AUnconventional myosin-VaCandidate gene tested inAltamente restrito
FUNÇÃO

Processive actin-based motor that can move in large steps approximating the 36-nm pseudo-repeat of the actin filament. Can hydrolyze ATP in the presence of actin, which is essential for its function as a motor protein (PubMed:10448864). Involved in melanosome transport. Also mediates the transport of vesicles to the plasma membrane (By similarity). May also be required for some polarization process involved in dendrite formation (By similarity)

LOCALIZAÇÃO

VIAS BIOLÓGICAS (5)
Regulation of actin dynamics for phagocytic cup formationFCGR3A-mediated phagocytosisTranslocation of SLC2A4 (GLUT4) to the plasma membraneRegulation of MITF-M-dependent genes involved in pigmentationInsulin processing
MECANISMO DE DOENÇA

Griscelli syndrome 1

Rare autosomal recessive disorder that results in pigmentary dilution of the skin and hair, the presence of large clumps of pigment in hair shafts, silvery-gray hair and accumulation of melanosomes in melanocytes. GS1 patients show developmental delay, hypotonia and intellectual disability, without apparent immune abnormalities.

EXPRESSÃO TECIDUAL(Ubíquo)
Cérebro - Hemisfério cerebelar
68.3 TPM
Cerebelo
59.0 TPM
Brain Frontal Cortex BA9
53.8 TPM
Córtex cerebral
36.2 TPM
Brain Anterior cingulate cortex BA24
33.8 TPM
OUTRAS DOENÇAS (3)
Griscelli syndrome type 1Griscelli syndrome type 3neuroectodermal melanolysosomal disease
HGNC:7602UniProt:Q9Y4I1
LIPT1Lipoyl amidotransferase LIPT1, mitochondrialCandidate gene tested inTolerante
FUNÇÃO

Lipoyl amidotransferase that catalyzes the transfer of lipoyl moieties from lipoyl-protein H of the glycine cleavage system (lipoyl-GCSH) to E2 subunits of the pyruvate dehydrogenase complex (PDCE2) (PubMed:29987032). Unable to catalyze the transfer of octanoyl from octanoyl-GCSH to PDCE2 (PubMed:29987032). In vitro, it is also able to catalyze the transfer of the lipoyl group from lipoyl-AMP to the specific lysine residue of lipoyl domains of lipoate-dependent enzymes but this reaction may not

LOCALIZAÇÃO

Mitochondrion

VIAS BIOLÓGICAS (1)
Protein lipoylation
MECANISMO DE DOENÇA

Lipoyltransferase 1 deficiency

An autosomal recessive disorder due to a defect in lipoic acid metabolism, resulting in severe lactic acidosis and metabolic decompensation. Variable clinical manifestations include delayed psychomotor development, severe hypotonia, dystonia, loss of head control, coma, bradycardia, and pulmonary hypertension.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
14.5 TPM
Tireoide
11.8 TPM
Baço
11.8 TPM
Ovário
11.5 TPM
Próstata
10.8 TPM
OUTRAS DOENÇAS (1)
lipoyl transferase 1 deficiency
HGNC:29569UniProt:Q9Y234
SLC10A1Hepatic sodium/bile acid cotransporterCandidate gene tested inTolerante
FUNÇÃO

As a major transporter of conjugated bile salts from plasma into the hepatocyte, it plays a key role in the enterohepatic circulation of bile salts necessary for the solubilization and absorption of dietary fat and fat-soluble vitamins (PubMed:14660639, PubMed:24867799, PubMed:34060352, PubMed:8132774). It is strictly dependent on the extracellular presence of sodium (PubMed:14660639, PubMed:24867799, PubMed:34060352, PubMed:8132774). It exhibits broad substrate specificity and transports variou

LOCALIZAÇÃO

Cell membrane

VIAS BIOLÓGICAS (1)
Recycling of bile acids and salts
MECANISMO DE DOENÇA

Hypercholanemia, familial, 2

An autosomal recessive inborn error of metabolism characterized by persistently increased plasma levels of conjugated bile salts apparent from infancy, fat malabsorption and impaired absorption of fat-soluble vitamins, including D and K. Most patients are asymptomatic. Some neonates may have transient jaundice or transiently elevated liver enzymes.

EXPRESSÃO TECIDUAL(Tecido-específico)
Fígado
94.3 TPM
Testículo
0.5 TPM
Cerebelo
0.4 TPM
Cérebro - Hemisfério cerebelar
0.4 TPM
Pituitária
0.2 TPM
OUTRAS DOENÇAS (2)
hypercholanemia, familial, 2hypercholanemia, familial 1
HGNC:10905UniProt:Q14973
TJP2Tight junction protein 2Candidate gene tested inTolerante
FUNÇÃO

Plays a role in tight junctions and adherens junctions (By similarity). Acts as a positive regulator of RANKL-induced osteoclast differentiation, potentially via mediating downstream transcriptional activity (By similarity)

LOCALIZAÇÃO

Cell junction, adherens junctionCell membraneCell junction, tight junctionNucleus

VIAS BIOLÓGICAS (1)
Signaling by Hippo
MECANISMO DE DOENÇA

Hypercholanemia, familial, 1

A disorder characterized by elevated serum bile acid concentrations, itching, and fat malabsorption.

EXPRESSÃO TECIDUAL(Ubíquo)
Aorta
103.6 TPM
Nervo tibial
85.5 TPM
Pulmão
84.2 TPM
Tecido adiposo
81.3 TPM
Tireoide
80.0 TPM
OUTRAS DOENÇAS (3)
cholestasis, progressive familial intrahepatic, 4hypercholanemia, familial 1autosomal dominant nonsyndromic hearing loss
HGNC:11828UniProt:Q9UDY2
GRM1Metabotropic glutamate receptor 1Candidate gene tested inAltamente restrito
FUNÇÃO

G-protein coupled receptor for glutamate. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Signaling activates a phosphatidylinositol-calcium second messenger system. May participate in the central action of glutamate in the CNS, such as long-term potentiation in the hippocampus and long-term depression in the cerebellum (PubMed:24603153, PubMed:28886343, PubMed:7476890).

LOCALIZAÇÃO

Cell membranePostsynaptic cell membraneCell projection, dendrite

VIAS BIOLÓGICAS (3)
G alpha (q) signalling eventsClass C/3 (Metabotropic glutamate/pheromone receptors)Neurexins and neuroligins
MECANISMO DE DOENÇA

Spinocerebellar ataxia, autosomal recessive, 13

A form of spinocerebellar ataxia, a clinically and genetically heterogeneous group of cerebellar disorders. Patients show progressive incoordination of gait and often poor coordination of hands, speech and eye movements, due to degeneration of the cerebellum with variable involvement of the brainstem and spinal cord. SCAR13 is characterized by delayed psychomotor development beginning in infancy. Affected individuals show mild to profound intellectual disability with poor or absent speech as well as gait and stance ataxia and hyperreflexia.

EXPRESSÃO TECIDUAL(Tecido-específico)
Cérebro - Hemisfério cerebelar
38.4 TPM
Cerebelo
30.6 TPM
Brain Frontal Cortex BA9
5.7 TPM
Córtex cerebral
3.6 TPM
Brain Anterior cingulate cortex BA24
3.6 TPM
OUTRAS DOENÇAS (3)
spinocerebellar ataxia 44autosomal recessive spinocerebellar ataxia 13chondromyxoid fibroma
HGNC:4593UniProt:Q13255
HGDHomogentisate 1,2-dioxygenaseCandidate gene tested inTolerante
FUNÇÃO

Catalyzes the conversion of homogentisate to maleylacetoacetate

LOCALIZAÇÃO

VIAS BIOLÓGICAS (1)
Tyrosine catabolism
MECANISMO DE DOENÇA

Alkaptonuria

An autosomal recessive error of metabolism characterized by an increase in the level of homogentisic acid. The clinical manifestations are urine that turns dark on standing and alkalinization, black ochronotic pigmentation of cartilage and collagenous tissues, and spine arthritis.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Tecido-específico)
Fígado
186.2 TPM
Tireoide
52.3 TPM
Rim - Córtex
44.3 TPM
Próstata
30.3 TPM
Rim - Medula
26.1 TPM
OUTRAS DOENÇAS (1)
alkaptonuria
HGNC:4892UniProt:Q93099
ACADVLVery long-chain acyl-CoA dehydrogenase, mitochondrialCandidate gene tested inTolerante
FUNÇÃO

Very long-chain specific acyl-CoA dehydrogenase is one of the acyl-CoA dehydrogenases that catalyze the first step of mitochondrial fatty acid beta-oxidation (FAO), breaking down fatty acids into acetyl-CoA and allowing the production of energy from fats (PubMed:17564966, PubMed:18227065, PubMed:7668252, PubMed:9461620, PubMed:9599005, PubMed:9839948). The first step of FAO consists in the proR-proR stereospecific alpha, beta-dehydrogenation of fatty acyl-CoA thioesters using the electron transf

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (2)
Beta oxidation of palmitoyl-CoA to myristoyl-CoAXBP1(S) activates chaperone genes
MECANISMO DE DOENÇA

Acyl-CoA dehydrogenase very long-chain deficiency

An inborn error of mitochondrial fatty acid beta-oxidation which leads to impaired long-chain fatty acid beta-oxidation. It is clinically heterogeneous, with three major phenotypes: a severe childhood form characterized by early onset, high mortality and high incidence of cardiomyopathy; a milder childhood form with later onset, characterized by hypoketotic hypoglycemia, low mortality and rare cardiomyopathy; an adult form, with isolated skeletal muscle involvement, rhabdomyolysis and myoglobinuria, usually triggered by exercise or fasting.

OUTRAS DOENÇAS (1)
very long chain acyl-CoA dehydrogenase deficiency
HGNC:92UniProt:P49748
MMACHCCyanocobalamin reductase / alkylcobalamin dealkylaseCandidate gene tested inTolerante
FUNÇÃO

Cobalamin (vitamin B12) cytosolic chaperone that catalyzes the reductive decyanation of cyanocob(III)alamin (cyanocobalamin, CNCbl) to yield cob(II)alamin and cyanide, using FAD or FMN as cofactors and NADPH as cosubstrate (PubMed:18779575, PubMed:19700356, PubMed:21697092, PubMed:25809485). Cyanocobalamin constitutes the inactive form of vitamin B12 introduced from the diet, and is converted into the active cofactors methylcobalamin (MeCbl) involved in methionine biosynthesis, and 5'-deoxyadeno

LOCALIZAÇÃO

Cytoplasm, cytosol

VIAS BIOLÓGICAS (2)
Cobalamin (Cbl) metabolismDefective MMADHC causes MMAHCD
MECANISMO DE DOENÇA

Methylmalonic aciduria and homocystinuria, cblC type

An autosomal recessive disorder of cobalamin metabolism characterized by decreased levels of the coenzymes adenosylcobalamin (AdoCbl) and methylcobalamin (MeCbl). Affected individuals may have developmental, hematologic, neurologic, metabolic, ophthalmologic, and dermatologic clinical findings. Although considered a disease of infancy or childhood, some individuals develop symptoms in adulthood.

EXPRESSÃO TECIDUAL(Ubíquo)
Fígado
9.1 TPM
Testículo
7.5 TPM
Fibroblastos
6.7 TPM
Linfócitos
5.8 TPM
Glândula adrenal
4.4 TPM
OUTRAS DOENÇAS (1)
methylmalonic aciduria and homocystinuria type cblC
HGNC:24525UniProt:Q9Y4U1
PDHBPyruvate dehydrogenase E1 component subunit beta, mitochondrialCandidate gene tested inRestrito
FUNÇÃO

Together with PDHA1 forms the heterotetrameric E1 subunit of the pyruvate dehydrogenase (PDH) complex (PubMed:17474719, PubMed:19081061). The PDH complex catalyzes the overall conversion of pyruvate to acetyl-CoA and CO(2), and thereby links cytoplasmic glycolysis and the mitochondrial tricarboxylic acid (TCA) cycle (Probable). It contains multiple copies of three enzymatic components: pyruvate dehydrogenase (E1), dihydrolipoamide acetyltransferase (E2) and dihydrolipoamide dehydrogenase (E3) (P

LOCALIZAÇÃO

Mitochondrion matrix

VIAS BIOLÓGICAS (4)
Signaling by Retinoic AcidRegulation of pyruvate dehydrogenase (PDH) complexPDH complex synthesizes acetyl-CoA from PYRMitochondrial protein degradation
MECANISMO DE DOENÇA

Pyruvate dehydrogenase E1-beta deficiency

An enzymatic defect causing primary lactic acidosis in children. It is associated with a broad clinical spectrum ranging from fatal lactic acidosis in the newborn to chronic neurologic dysfunction with structural abnormalities in the central nervous system without systemic acidosis.

EXPRESSÃO TECIDUAL(Ubíquo)
Músculo esquelético
122.9 TPM
Esôfago - Muscular
118.3 TPM
Fibroblastos
115.0 TPM
Coração - Ventrículo esquerdo
110.6 TPM
Artéria tibial
106.5 TPM
OUTRAS DOENÇAS (1)
pyruvate dehydrogenase E1-beta deficiency
HGNC:8808UniProt:P11177
PDP1Polyisoprenoid diphosphate/phosphate phosphohydrolase PLPP6Candidate gene tested inRestrito
FUNÇÃO

Magnesium-independent polyisoprenoid diphosphatase that catalyzes the sequential dephosphorylation of presqualene, farnesyl, geranyl and geranylgeranyl diphosphates (PubMed:16464866, PubMed:19220020, PubMed:20110354). Functions in the innate immune response through the dephosphorylation of presqualene diphosphate which acts as a potent inhibitor of the signaling pathways contributing to polymorphonuclear neutrophils activation (PubMed:16464866, PubMed:23568778). May regulate the biosynthesis of

LOCALIZAÇÃO

Endoplasmic reticulum membraneNucleus envelopeNucleus inner membrane

VIAS BIOLÓGICAS (1)
Regulation of pyruvate dehydrogenase (PDH) complex
VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Brain Frontal Cortex BA9
51.5 TPM
Glândula adrenal
34.6 TPM
Testículo
29.8 TPM
Córtex cerebral
28.2 TPM
Fibroblastos
20.0 TPM
OUTRAS DOENÇAS (1)
pyruvate dehydrogenase phosphatase deficiency
HGNC:9279UniProt:Q8IY26
DLATDihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase complex, mitochondrialCandidate gene tested inTolerante
FUNÇÃO

The pyruvate dehydrogenase (PDH) complex, catalyzes the overall conversion of pyruvate to acetyl-CoA and CO(2), and thereby links cytoplasmic glycolysis and the mitochondrial tricarboxylic acid (TCA) cycle (Probable). It contains multiple copies of three enzymatic components: pyruvate dehydrogenase (E1), dihydrolipoamide acetyltransferase (E2) and dihydrolipoamide dehydrogenase (E3); (Probable). Within this complex, the catalytic function of this enzyme is to accept, and to transfer to coenzyme

LOCALIZAÇÃO

Mitochondrion matrix

VIAS BIOLÓGICAS (3)
PDH complex synthesizes acetyl-CoA from PYRProtein lipoylationRegulation of pyruvate dehydrogenase (PDH) complex
EXPRESSÃO TECIDUAL(Ubíquo)
Músculo esquelético
38.4 TPM
Linfócitos
37.6 TPM
Coração - Ventrículo esquerdo
36.5 TPM
Fibroblastos
31.1 TPM
Coração - Átrio
26.7 TPM
OUTRAS DOENÇAS (1)
pyruvate dehydrogenase E2 deficiency
HGNC:2896UniProt:P10515
SLC1A1Excitatory amino acid transporter 3Candidate gene tested inTolerante
FUNÇÃO

Sodium-dependent, high-affinity amino acid transporter that mediates the uptake of L-glutamate and also L-aspartate and D-aspartate (PubMed:21123949, PubMed:26690923, PubMed:33658209, PubMed:7521911, PubMed:7914198, PubMed:8857541). Can also transport L-cysteine (PubMed:21123949). Functions as a symporter that transports one amino acid molecule together with two or three Na(+) ions and one proton, in parallel with the counter-transport of one K(+) ion (PubMed:26690923, PubMed:33658209, PubMed:75

LOCALIZAÇÃO

Cell membraneApical cell membraneSynapse, synaptosomeEarly endosome membraneLate endosome membraneRecycling endosome membrane

VIAS BIOLÓGICAS (2)
Glutamate Neurotransmitter Release CycleSLC-mediated transport of amino acids
MECANISMO DE DOENÇA

Dicarboxylic aminoaciduria

An autosomal recessive disorder characterized by abnormal excretion of urinary glutamate and aspartate, resulting from the incomplete reabsorption of anionic amino acids from the glomerular filtrate in the kidney. It can be associated with intellectual disability.

EXPRESSÃO TECIDUAL(Ubíquo)
Tireoide
33.4 TPM
Linfócitos
26.3 TPM
Fígado
23.9 TPM
Intestino delgado
22.8 TPM
Brain Frontal Cortex BA9
20.2 TPM
OUTRAS DOENÇAS (3)
dicarboxylic aminoaciduriahot water reflex epilepsyschizophrenia 18
HGNC:10939UniProt:P43005
AASSAlpha-aminoadipic semialdehyde synthase, mitochondrialCandidate gene tested inTolerante
FUNÇÃO

Bifunctional enzyme that catalyzes the first two steps in lysine degradation

LOCALIZAÇÃO

Mitochondrion

VIAS BIOLÓGICAS (1)
Lysine catabolism
MECANISMO DE DOENÇA

Hyperlysinemia, 1

An autosomal recessive metabolic condition with variable clinical features. Some patients present with non-specific seizures, hypotonia, or mildly delayed psychomotor development, and increased serum lysine and pipecolic acid on laboratory analysis. However, about half of the probands are reported to be asymptomatic, and hyperlysinemia is generally considered to be a benign metabolic variant.

VIAS REACTOME (1)
OUTRAS DOENÇAS (2)
hyperlysinemiasaccharopinuria
HGNC:17366UniProt:Q9UDR5
SLC24A5Sodium/potassium/calcium exchanger 5Candidate gene tested inTolerante
FUNÇÃO

Calcium, potassium:sodium antiporter that transports 1 Ca(2+) and 1 K(+) to the melanosome in exchange for 4 cytoplasmic Na(+) (PubMed:18166528). Involved in pigmentation, possibly by participating in ion transport in melanosomes (PubMed:16357253, PubMed:18166528). Predominant sodium-calcium exchanger in melanocytes (PubMed:16357253, PubMed:18166528)

LOCALIZAÇÃO

Golgi apparatus, trans-Golgi network membraneMelanosome

VIAS BIOLÓGICAS (1)
Sodium/Calcium exchangers
MECANISMO DE DOENÇA

Albinism, oculocutaneous, 6

A disorder characterized by a reduction or complete loss of melanin in the skin, hair and eyes. Patients show reduced or lacking pigmentation often accompanied by eye symptoms such as photophobia, strabismus, moderate to severe visual impairment, and nystagmus.

EXPRESSÃO TECIDUAL(Não detectado)
Skin Not Sun Exposed Suprapubic
0.3 TPM
Skin Sun Exposed Lower leg
0.3 TPM
Testículo
0.2 TPM
Pituitária
0.1 TPM
Cérebro - Hemisfério cerebelar
0.1 TPM
OUTRAS DOENÇAS (1)
oculocutaneous albinism type 6
HGNC:20611UniProt:Q71RS6
SLC25A13Electrogenic aspartate/glutamate antiporter SLC25A13, mitochondrialCandidate gene tested inTolerante
FUNÇÃO

Mitochondrial electrogenic aspartate/glutamate antiporter that favors efflux of aspartate and entry of glutamate and proton within the mitochondria as part of the malate-aspartate shuttle (PubMed:11566871, PubMed:38937634, PubMed:38945283, PubMed:39419476). Substrate exchange across the membrane occurs consecutively with one substrate being transported first, then dissociating from the substrate binding site before the second substrate binds for transport in the opposite direction (PubMed:389376

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (2)
Aspartate and asparagine metabolismMalate-aspartate shuttle
MECANISMO DE DOENÇA

Citrin deficiency, adolescent or adult onset

An autosomal recessive metabolic disorder characterized by elevated serum and urine citrulline levels, ammonia intoxication, and neuropsychiatric symptoms including abnormal behaviors, loss of memory, seizures and coma. Death can result from brain edema.

EXPRESSÃO TECIDUAL(Ubíquo)
Fígado
44.3 TPM
Brain Spinal cord cervical c-1
21.7 TPM
Skin Sun Exposed Lower leg
21.1 TPM
Cervix Endocervix
19.9 TPM
Glândula adrenal
19.0 TPM
OUTRAS DOENÇAS (3)
citrullinemia, type II, adult-onsetneonatal intrahepatic cholestasis due to citrin deficiencycitrullinemia type II
HGNC:10983UniProt:Q9UJS0
OATOrnithine aminotransferase, mitochondrialCandidate gene tested inTolerante
FUNÇÃO

Catalyzes the reversible interconversion of L-ornithine and 2-oxoglutarate to L-glutamate semialdehyde and L-glutamate

LOCALIZAÇÃO

Mitochondrion matrix

VIAS BIOLÓGICAS (1)
Glutamate and glutamine metabolism
MECANISMO DE DOENÇA

Hyperornithinemia with gyrate atrophy of choroid and retina

A disorder clinically characterized by a triad of progressive chorioretinal degeneration, early cataract formation, and type II muscle fiber atrophy. Characteristic chorioretinal atrophy with progressive constriction of the visual fields leads to blindness at the latest during the sixth decade of life. Patients generally have normal intelligence.

EXPRESSÃO TECIDUAL(Ubíquo)
Intestino delgado
165.3 TPM
Fibroblastos
139.5 TPM
Aorta
118.9 TPM
Artéria tibial
116.9 TPM
Cervix Endocervix
110.6 TPM
OUTRAS DOENÇAS (1)
ornithine aminotransferase deficiency
HGNC:8091UniProt:P04181
PRODHProline dehydrogenase 1, mitochondrialCandidate gene tested inDesconhecido
FUNÇÃO

Converts proline to delta-1-pyrroline-5-carboxylate

LOCALIZAÇÃO

Mitochondrion matrix

VIAS BIOLÓGICAS (1)
Proline catabolism
MECANISMO DE DOENÇA

Hyperprolinemia 1

An inborn error of proline metabolism resulting in elevated levels of proline in the plasma and urine. The disorder is generally benign and most affected individuals are clinically asymptomatic. Some patients, however, have neurologic manifestations, including epilepsy and intellectual disability. Association with certain forms of schizophrenia have been reported.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Nervo tibial
62.7 TPM
Skin Sun Exposed Lower leg
61.6 TPM
Skin Not Sun Exposed Suprapubic
56.9 TPM
Córtex cerebral
50.8 TPM
Brain Anterior cingulate cortex BA24
44.0 TPM
OUTRAS DOENÇAS (2)
hyperprolinemia type 1schizophrenia 4
HGNC:9453UniProt:O43272
SUGCTSuccinyl-CoA:glutarate CoA-transferaseCandidate gene tested inTolerante
FUNÇÃO

Coenzyme A (CoA) transferase that reversibly catalyzes the transfer of a CoA moiety from a dicarboxyl-CoA to a dicarboxylate in a metabolite recycling process. Displays preference for succinyl-CoA and glutarate-CoA as dicarboxyl-CoA donors and glutarate, succinate, adipate/hexanedioate, itaconate and 3-hydroxy-3-methylglutarate as dicarboxylate acceptors (PubMed:23893049, PubMed:34492704, PubMed:38915184). Acts on intermediates or end products of lysine and tryptophan degradation pathway, in par

LOCALIZAÇÃO

Mitochondrion

MECANISMO DE DOENÇA

Glutaric aciduria 3

An autosomal recessive metabolic condition characterized by urinary excretion of abnormal quantities of glutaric acid, in the presence of normal 3-hydroxyglutarate, glutarylcarnitine and glutarylglycine urinary levels. Affected individuals show no consistent clinical phenotype and many are asymptomatic.

EXPRESSÃO TECIDUAL(Ubíquo)
Aorta
26.0 TPM
Artéria coronária
15.9 TPM
Fibroblastos
15.3 TPM
Glândula adrenal
14.8 TPM
Artéria tibial
9.7 TPM
OUTRAS DOENÇAS (1)
glutaric acidemia type 3
HGNC:16001UniProt:Q9HAC7
KYNUKynureninaseCandidate gene tested inTolerante
FUNÇÃO

Catalyzes the cleavage of L-kynurenine (L-Kyn) and L-3-hydroxykynurenine (L-3OHKyn) into anthranilic acid (AA) and 3-hydroxyanthranilic acid (3-OHAA), respectively. Has a preference for the L-3-hydroxy form. Also has cysteine-conjugate-beta-lyase activity

LOCALIZAÇÃO

Cytoplasm, cytosol

VIAS BIOLÓGICAS (1)
Tryptophan catabolism
MECANISMO DE DOENÇA

Hydroxykynureninuria

An inborn error of amino acid metabolism characterized by massive urinary excretion of large amounts of kynurenine, 3-hydroxykynurenine and xanthurenic acid. Affected individuals manifest renal tubular dysfunction, metabolic acidosis, psychomotor retardation, non-progressive encephalopathy, and muscular hypertonia.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Tecido-específico)
Linfócitos
6.9 TPM
Fígado
3.7 TPM
Testículo
2.6 TPM
Pulmão
2.2 TPM
Baço
1.9 TPM
OUTRAS DOENÇAS (3)
vertebral, cardiac, renal, and limb defects syndrome 2encephalopathy due to hydroxykynureninuriacongenital vertebral-cardiac-renal anomalies syndrome
HGNC:6469UniProt:Q16719
DHTKD12-oxoadipate dehydrogenase complex component E1Candidate gene tested inTolerante
FUNÇÃO

2-oxoadipate dehydrogenase (E1a) component of the 2-oxoadipate dehydrogenase complex (OADHC) (PubMed:29191460, PubMed:29752936, PubMed:32303640, PubMed:32633484, PubMed:32695416). Participates in the first step, rate limiting for the overall conversion of 2-oxoadipate (alpha-ketoadipate) to glutaryl-CoA and CO(2) catalyzed by the whole OADHC (PubMed:29191460, PubMed:32695416). Catalyzes the irreversible decarboxylation of 2-oxoadipate via the thiamine diphosphate (ThDP) cofactor and subsequent t

LOCALIZAÇÃO

Mitochondrion

VIAS BIOLÓGICAS (1)
OADH complex synthesizes glutaryl-CoA from 2-OA
MECANISMO DE DOENÇA

Charcot-Marie-Tooth disease, axonal, type 2Q

An axonal form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathies (designated CMT1 when they are dominantly inherited) and primary peripheral axonal neuropathies (CMT2). Neuropathies of the CMT2 group are characterized by signs of axonal degeneration in the absence of obvious myelin alterations, normal or slightly reduced nerve conduction velocities, and progressive distal muscle weakness and atrophy.

EXPRESSÃO TECIDUAL(Ubíquo)
Fígado
51.2 TPM
Linfócitos
43.7 TPM
Ovário
22.0 TPM
Nervo tibial
17.9 TPM
Tireoide
17.1 TPM
OUTRAS DOENÇAS (2)
Charcot-Marie-Tooth disease axonal type 2Q2-aminoadipic 2-oxoadipic aciduria
HGNC:23537UniProt:Q96HY7
ABCC8ATP-binding cassette sub-family C member 8Candidate gene tested inTolerante
FUNÇÃO

Regulator subunit of pancreatic ATP-sensitive potassium channel (KATP), playing a major role in the regulation of insulin release. In pancreatic cells, it forms KATP channels with KCNJ11; KCNJ11 forms the channel pore while ABCC8 is required for activation and regulation

LOCALIZAÇÃO

Cell membrane

VIAS BIOLÓGICAS (2)
Regulation of insulin secretionATP sensitive Potassium channels
MECANISMO DE DOENÇA

Leucine-induced hypoglycemia

Rare cause of hypoglycemia and is described as a condition in which symptomatic hypoglycemia is provoked by high protein feedings. Hypoglycemia is also elicited by administration of oral or intravenous infusions of a single amino acid, leucine.

OUTRAS DOENÇAS (12)
hyperinsulinemic hypoglycemia, familial, 1diabetes mellitus, transient neonatal, 2diabetes mellitus, permanent neonatal 3hypoglycemia, leucine-induced
HGNC:59UniProt:Q09428
ABAT4-aminobutyrate aminotransferase, mitochondrialCandidate gene tested inTolerante
FUNÇÃO

Catalyzes the conversion of gamma-aminobutyrate and L-beta-aminoisobutyrate to succinate semialdehyde and methylmalonate semialdehyde, respectively (PubMed:10407778, PubMed:15528998). Can also convert delta-aminovalerate and beta-alanine (By similarity)

LOCALIZAÇÃO

Mitochondrion matrix

VIAS BIOLÓGICAS (1)
Degradation of GABA
MECANISMO DE DOENÇA

GABA-transaminase deficiency

An enzymatic deficiency resulting in psychomotor retardation, hypotonia, hyperreflexia, lethargy, refractory seizures, and EEG abnormalities. GABATD inheritance is autosomal recessive.

VIAS REACTOME (1)
OUTRAS DOENÇAS (1)
GABA aminotransaminase deficiency
HGNC:23UniProt:P80404
MCCC1Methylcrotonoyl-CoA carboxylase subunit alpha, mitochondrialCandidate gene tested inTolerante
FUNÇÃO

Biotin-attachment subunit of the 3-methylcrotonyl-CoA carboxylase, an enzyme that catalyzes the conversion of 3-methylcrotonyl-CoA to 3-methylglutaconyl-CoA, a critical step for leucine and isovaleric acid catabolism

LOCALIZAÇÃO

Mitochondrion matrix

VIAS BIOLÓGICAS (2)
Defective HLCS causes multiple carboxylase deficiencyBiotin transport and metabolism
MECANISMO DE DOENÇA

3-methylcrotonoyl-CoA carboxylase 1 deficiency

An autosomal recessive disorder of leucine catabolism. The phenotype is variable, ranging from neonatal onset with severe neurological involvement to asymptomatic adults. There is a characteristic organic aciduria with massive excretion of 3-hydroxyisovaleric acid and 3-methylcrotonylglycine, usually in combination with a severe secondary carnitine deficiency.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
35.9 TPM
Ovário
28.1 TPM
Glândula adrenal
26.9 TPM
Tireoide
25.8 TPM
Nervo tibial
25.6 TPM
OUTRAS DOENÇAS (2)
3-methylcrotonyl-CoA carboxylase 1 deficiency3-methylcrotonyl-CoA carboxylase deficiency
HGNC:6936UniProt:Q96RQ3
PMPCBMitochondrial-processing peptidase subunit betaDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalytic subunit of the essential mitochondrial processing protease (MPP), which cleaves the mitochondrial sequence off newly imported precursors proteins (Probable) (PubMed:29576218). Preferentially, cleaves after an arginine at position P2 (By similarity). Required for PINK1 turnover by coupling PINK1 mitochondrial import and cleavage, which results in subsequent PINK1 proteolysis (PubMed:22354088)

LOCALIZAÇÃO

Mitochondrion matrix

VIAS BIOLÓGICAS (2)
Mitochondrial protein importProcessing of SMDT1
MECANISMO DE DOENÇA

Multiple mitochondrial dysfunctions syndrome 6

An autosomal recessive, neurodegenerative disorder characterized by basal ganglia lesions, cerebellar atrophy, and neurologic regression in the first year of life. Common features include truncal hypotonia, lack of independent ambulation, poor speech, intellectual disability, and motor abnormalities, such as ataxia, dystonia, and spasticity.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
85.0 TPM
Ovário
68.1 TPM
Cervix Endocervix
66.3 TPM
Útero
65.9 TPM
Artéria tibial
64.7 TPM
OUTRAS DOENÇAS (1)
multiple mitochondrial dysfunctions syndrome 6
HGNC:9119UniProt:O75439
ISCA2Iron-sulfur cluster assembly 2 homolog, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Involved in the maturation of mitochondrial 4Fe-4S proteins functioning late in the iron-sulfur cluster assembly pathway. May be involved in the binding of an intermediate of Fe/S cluster assembly

LOCALIZAÇÃO

Mitochondrion

VIAS BIOLÓGICAS (2)
Maturation of TCA enzymes and regulation of TCA cycleMitochondrial iron-sulfur cluster biogenesis
MECANISMO DE DOENÇA

Multiple mitochondrial dysfunctions syndrome 4

A severe disorder of systemic energy metabolism, resulting in weakness, respiratory failure, lack of neurologic development, lactic acidosis, hyperglycinemia and early death.

EXPRESSÃO TECIDUAL(Ubíquo)
Tireoide
21.5 TPM
Linfócitos
20.0 TPM
Glândula adrenal
18.8 TPM
Fibroblastos
18.2 TPM
Testículo
17.7 TPM
OUTRAS DOENÇAS (1)
multiple mitochondrial dysfunctions syndrome 4
HGNC:19857UniProt:Q86U28
MPC1Mitochondrial pyruvate carrier 1Disease-causing germline mutation(s) inModerado
FUNÇÃO

Mediates the uptake of pyruvate into mitochondria to maintain the balance between glycolysis and oxidative phosphorylation (PubMed:22628558, PubMed:26253029, PubMed:27317664, PubMed:40044865, PubMed:40101766). Plays an essential role in cellular metabolism (PubMed:40044865, PubMed:40101766)

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (1)
Pyruvate metabolism
MECANISMO DE DOENÇA

Mitochondrial pyruvate carrier deficiency

An autosomal recessive metabolic disorder characterized by severely delayed psychomotor development, mild dysmorphic features, hepatomegaly, marked metabolic acidosis, hyperlactacidemia with normal lactate/pyruvate, and encephalopathy. Some patients have epilepsy and peripheral neuropathy.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Coração - Ventrículo esquerdo
168.8 TPM
Brain Spinal cord cervical c-1
164.5 TPM
Coração - Átrio
144.6 TPM
Rim - Medula
132.4 TPM
Fígado
131.9 TPM
INTERAÇÕES PROTEICAS (1)
OUTRAS DOENÇAS (1)
mitochondrial pyruvate carrier deficiency
HGNC:21606UniProt:Q9Y5U8
MCEEMethylmalonyl-CoA epimerase, mitochondrialDisease-causing germline mutation(s) inModerado
FUNÇÃO

Methylmalonyl-CoA epimerase involved in propionyl-CoA metabolism

LOCALIZAÇÃO

Mitochondrion

VIAS BIOLÓGICAS (1)
Propionyl-CoA catabolism
MECANISMO DE DOENÇA

Methylmalonyl-CoA epimerase deficiency

Autosomal recessive inborn error of amino acid metabolism, involving valine, threonine, isoleucine and methionine. This organic aciduria may present in the neonatal period with life-threatening metabolic acidosis, hyperammonemia, feeding difficulties, pancytopenia and coma.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Pituitária
22.7 TPM
Cervix Ectocervix
22.6 TPM
Cervix Endocervix
22.1 TPM
Glândula salivar
20.9 TPM
Glândula adrenal
20.5 TPM
OUTRAS DOENÇAS (1)
methylmalonic acidemia due to methylmalonyl-CoA epimerase deficiency
HGNC:16732UniProt:Q96PE7
MMAAPutative L-type amino acid transporter 1-like protein IMAADisease-causing germline mutation(s) inTolerante
LOCALIZAÇÃO

Membrane

VIAS BIOLÓGICAS (3)
Cobalamin (Cbl) metabolismPropionyl-CoA catabolismDefective MUT causes MMAM
EXPRESSÃO TECIDUAL(Ubíquo)
Fígado
5.2 TPM
Linfócitos
4.6 TPM
Testículo
3.8 TPM
Fibroblastos
3.6 TPM
Cérebro - Hemisfério cerebelar
3.5 TPM
OUTRAS DOENÇAS (1)
methylmalonic aciduria, cblA type
HGNC:18871UniProt:Q9GIP4
LMBRD1Lysosomal cobalamin transport escort protein LMBD1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Lysosomal membrane chaperone required to export cobalamin (vitamin B12) from the lysosome to the cytosol, allowing its conversion to cofactors (PubMed:19136951). Targets ABCD4 transporter from the endoplasmic reticulum to the lysosome (PubMed:27456980). Then forms a complex with lysosomal ABCD4 and cytoplasmic MMACHC to transport cobalamin across the lysosomal membrane (PubMed:25535791). Acts as an adapter protein which plays an important role in mediating and regulating the internalization of t

LOCALIZAÇÃO

Endoplasmic reticulum membraneLysosome membraneCell membraneCytoplasmic vesicle, clathrin-coated vesicle

VIAS BIOLÓGICAS (3)
Transport of RCbl within the bodyUptake of dietary cobalamins into enterocytesDefective ABCD4 causes MAHCJ
MECANISMO DE DOENÇA

Methylmalonic aciduria and homocystinuria, cblF type

An autosomal recessive disorder of cobalamin metabolism characterized by decreased levels of the coenzymes adenosylcobalamin (AdoCbl) and methylcobalamin (MeCbl). It is due to accumulation of free cobalamin in lysosomes, thus hindering its conversion to cofactors. Clinical features include developmental delay, stomatitis, glossitis, seizures and methylmalonic aciduria responsive to vitamin B12.

EXPRESSÃO TECIDUAL(Ubíquo)
Brain Spinal cord cervical c-1
108.4 TPM
Nervo tibial
106.7 TPM
Cérebro - Hemisfério cerebelar
91.9 TPM
Tireoide
82.0 TPM
Glândula adrenal
77.1 TPM
OUTRAS DOENÇAS (1)
methylmalonic aciduria and homocystinuria type cblF
HGNC:23038UniProt:Q9NUN5
HCFC1Host cell factor 1Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Transcriptional coregulator (By similarity). Serves as a scaffold protein, bridging interactions between transcription factors, including THAP11 and ZNF143, and transcriptional coregulators (PubMed:26416877). Involved in control of the cell cycle (PubMed:10629049, PubMed:10779346, PubMed:15190068, PubMed:16624878, PubMed:23629655). Also antagonizes transactivation by ZBTB17 and GABP2; represses ZBTB17 activation of the p15(INK4b) promoter and inhibits its ability to recruit p300 (PubMed:10675337

LOCALIZAÇÃO

CytoplasmNucleus

VIAS BIOLÓGICAS (4)
HATs acetylate histonesFormation of WDR5-containing histone-modifying complexesTranscriptional activation of mitochondrial biogenesisUCH proteinases
MECANISMO DE DOENÇA

Methylmalonic aciduria and homocystinuria, cblX type

An X-linked recessive metabolic disorder characterized by severely delayed psychomotor development apparent in infancy, failure to thrive, impaired intellectual development, and intractable epilepsy. Additional features may include microcephaly and choreoathetosis.

EXPRESSÃO TECIDUAL(Ubíquo)
Útero
47.3 TPM
Linfócitos
43.8 TPM
Cerebelo
38.2 TPM
Fallopian Tube
37.2 TPM
Ovário
35.7 TPM
OUTRAS DOENÇAS (2)
methylmalonic acidemia with homocystinuria, type cblXnon-syndromic X-linked intellectual disability
HGNC:4839UniProt:P51610
ALDH6A1Methylmalonate-semialdehyde/malonate-semialdehyde dehydrogenase [acylating], mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Malonate and methylmalonate semialdehyde dehydrogenase involved in the catabolism of valine, thymine, and compounds catabolized by way of beta-alanine, including uracil and cytidine

LOCALIZAÇÃO

Mitochondrion

VIAS BIOLÓGICAS (1)
Branched-chain amino acid catabolism
MECANISMO DE DOENÇA

Methylmalonate semialdehyde dehydrogenase deficiency

A metabolic disorder characterized by elevated beta-alanine, 3-hydroxypropionic acid, and both isomers of 3-amino and 3-hydroxyisobutyric acids in urine organic acids.

OUTRAS DOENÇAS (1)
methylmalonate semialdehyde dehydrogenase deficiency
HGNC:7179UniProt:Q02252
BLKTyrosine-protein kinase BlkDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Non-receptor tyrosine kinase involved in B-lymphocyte development, differentiation and signaling (By similarity). B-cell receptor (BCR) signaling requires a tight regulation of several protein tyrosine kinases and phosphatases, and associated coreceptors (By similarity). Binding of antigen to the B-cell antigen receptor (BCR) triggers signaling that ultimately leads to B-cell activation (By similarity). Signaling through BLK plays an important role in transmitting signals through surface immunog

LOCALIZAÇÃO

Cell membrane

VIAS BIOLÓGICAS (1)
RUNX1 regulates transcription of genes involved in BCR signaling
MECANISMO DE DOENÇA

Maturity-onset diabetes of the young 11

A form of diabetes that is characterized by an autosomal dominant mode of inheritance, onset in childhood or early adulthood (usually before 25 years of age), a primary defect in insulin secretion and frequent insulin-independence at the beginning of the disease.

OUTRAS DOENÇAS (3)
maturity-onset diabetes of the young type 11systemic lupus erythematosusmaturity-onset diabetes of the young
HGNC:1057UniProt:P51451
INSInsulinDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Insulin decreases blood glucose concentration. It increases cell permeability to monosaccharides, amino acids and fatty acids. It accelerates glycolysis, the pentose phosphate cycle, and glycogen synthesis in liver

LOCALIZAÇÃO

Secreted

VIAS BIOLÓGICAS (2)
Insulin receptor recyclingSignaling by Insulin receptor
MECANISMO DE DOENÇA

Hyperproinsulinemia

An autosomal dominant condition characterized by elevated levels of serum proinsulin-like material.

EXPRESSÃO TECIDUAL(Tecido-específico)
Pâncreas
2325.3 TPM
Glândula adrenal
0.5 TPM
Cervix Ectocervix
0.5 TPM
Substância negra
0.4 TPM
Baço
0.3 TPM
OUTRAS DOENÇAS (6)
maturity-onset diabetes of the young type 10diabetes mellitus, permanent neonatal 4hyperproinsulinemiatype 1 diabetes mellitus 2
HGNC:6081UniProt:P01308
SLC25A15Mitochondrial ornithine transporter 1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Mitochondrial ornithine-citrulline antiporter (Probable) (PubMed:12807890, PubMed:22262851). Catalyzes the exchange between cytosolic ornithine and mitochondrial citrulline plus an H(+), the proton compensates the positive charge of ornithine thus leading to an electroneutral transport. Plays a crucial role in the urea cycle, by connecting the cytosolic and the intramitochondrial reactions of the urea cycle (Probable) (PubMed:12807890, PubMed:22262851). Lysine and arginine are also transported b

LOCALIZAÇÃO

Mitochondrion inner membraneMitochondrion membrane

VIAS BIOLÓGICAS (1)
Urea cycle
MECANISMO DE DOENÇA

Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome

An autosomal recessive disorder of the urea cycle characterized by onset in early life. The acute phase of the disease is characterized by vomiting, ataxia, lethargy, confusion, and coma. Chronic clinical manifestations include hypotonia, developmental delay, progressive encephalopathy with mental regression, and spastic paraparesis with pyramidal signs.

EXPRESSÃO TECIDUAL(Ubíquo)
Fígado
30.0 TPM
Fibroblastos
13.7 TPM
Pâncreas
13.3 TPM
Testículo
12.7 TPM
Linfócitos
11.6 TPM
INTERAÇÕES PROTEICAS (3)
OUTRAS DOENÇAS (1)
ornithine translocase deficiency
HGNC:10985UniProt:Q9Y619
DTNBP1DysbindinDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Component of the BLOC-1 complex, a complex that is required for normal biogenesis of lysosome-related organelles (LRO), such as platelet dense granules and melanosomes. In concert with the AP-3 complex, the BLOC-1 complex is required to target membrane protein cargos into vesicles assembled at cell bodies for delivery into neurites and nerve terminals. The BLOC-1 complex, in association with SNARE proteins, is also proposed to be involved in neurite extension. Associates with the BLOC-2 complex

LOCALIZAÇÃO

CytoplasmCytoplasmic vesicle membraneEndosome membraneMelanosome membranePostsynaptic densityEndoplasmic reticulumNucleusCytoplasmic vesicle, secretory vesicle, synaptic vesicle membranePostsynaptic cell membrane

VIAS BIOLÓGICAS (1)
Golgi Associated Vesicle Biogenesis
MECANISMO DE DOENÇA

Hermansky-Pudlak syndrome 7

A form of Hermansky-Pudlak syndrome, a genetically heterogeneous autosomal recessive disorder characterized by oculocutaneous albinism, bleeding due to platelet storage pool deficiency, and lysosomal storage defects. This syndrome results from defects of diverse cytoplasmic organelles including melanosomes, platelet dense granules and lysosomes. Ceroid storage in the lungs is associated with pulmonary fibrosis, a common cause of premature death in individuals with HPS.

EXPRESSÃO TECIDUAL(Ubíquo)
Brain Nucleus accumbens basal ganglia
37.2 TPM
Artéria tibial
29.7 TPM
Aorta
25.4 TPM
Cólon sigmoide
24.0 TPM
Brain Frontal Cortex BA9
21.5 TPM
OUTRAS DOENÇAS (1)
Hermansky-Pudlak syndrome 7
HGNC:17328UniProt:Q96EV8
SLC6A9Sodium- and chloride-dependent glycine transporter 1Disease-causing germline mutation(s) inRestrito
FUNÇÃO

Sodium- and chloride-dependent glycine transporter (PubMed:8183239). Essential for regulating glycine concentrations at inhibitory glycinergic synapses Sodium- and chloride-dependent glycine transporter Sodium- and chloride-dependent glycine transporter

LOCALIZAÇÃO

Cell membrane

VIAS BIOLÓGICAS (1)
SLC-mediated transport of neurotransmitters
MECANISMO DE DOENÇA

Glycine encephalopathy with normal serum glycine

An autosomal recessive, severe metabolic disorder characterized by arthrogryposis multiplex congenita, joint hyperlaxity, lack of neonatal respiratory effort, axial hypotonia, hypertonia with pronounced clonus, and delayed psychomotor development. Some patients may have dysmorphic facial features and/or brain imaging abnormalities. Laboratory studies show increased CSF glycine and normal or only mildly increased serum glycine. Most patients die in infancy.

EXPRESSÃO TECIDUAL(Ubíquo)
Brain Spinal cord cervical c-1
70.3 TPM
Skin Sun Exposed Lower leg
58.6 TPM
Skin Not Sun Exposed Suprapubic
49.2 TPM
Vagina
24.5 TPM
Substância negra
24.3 TPM
INTERAÇÕES PROTEICAS (1)
OUTRAS DOENÇAS (2)
atypical glycine encephalopathyinfantile glycine encephalopathy
HGNC:11056UniProt:P48067
AMTAminomethyltransferase, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

The glycine cleavage system catalyzes the degradation of glycine

LOCALIZAÇÃO

Mitochondrion

VIAS BIOLÓGICAS (1)
Glycine degradation
MECANISMO DE DOENÇA

Glycine encephalopathy 2

A form of glycine encephalopathy, a metabolic disorder characterized by a high concentration of glycine in the body fluids. Affected individuals typically have severe neurological symptoms, including seizure, lethargy, and muscular hypotonia soon after birth. Most of them die within the neonatal period. Atypical cases have later disease onset and less severely affected psychomotor development.

VIAS REACTOME (1)
OUTRAS DOENÇAS (4)
glycine encephalopathy 2infantile glycine encephalopathyneonatal glycine encephalopathyatypical glycine encephalopathy
HGNC:473UniProt:P48728
LDHBL-lactate dehydrogenase B chainDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Interconverts simultaneously and stereospecifically pyruvate and lactate with concomitant interconversion of NADH and NAD(+)

LOCALIZAÇÃO

CytoplasmMitochondrion inner membrane

VIAS BIOLÓGICAS (1)
Pyruvate metabolism
MECANISMO DE DOENÇA

Lactate dehydrogenase B deficiency

A condition with no deleterious effects on health. LDHBD is of interest to laboratory medicine mainly because it can cause misdiagnosis in those disorders in which elevation of serum LDH is expected.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
1127.9 TPM
Coração - Ventrículo esquerdo
873.8 TPM
Rim - Medula
786.4 TPM
Fibroblastos
738.5 TPM
Rim - Córtex
622.3 TPM
OUTRAS DOENÇAS (1)
glycogen storage disease due to lactate dehydrogenase H-subunit deficiency
HGNC:6541UniProt:P07195
PKLRPyruvate kinase PKLRDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Pyruvate kinase that catalyzes the conversion of phosphoenolpyruvate to pyruvate with the synthesis of ATP, and which plays a key role in glycolysis

LOCALIZAÇÃO

VIAS BIOLÓGICAS (3)
Pyruvate metabolismGlycolysisChREBP activates metabolic gene expression
MECANISMO DE DOENÇA

Pyruvate kinase hyperactivity

Autosomal dominant phenotype characterized by increase of red blood cell ATP.

EXPRESSÃO TECIDUAL(Tecido-específico)
Fígado
34.4 TPM
Rim - Córtex
8.2 TPM
Intestino delgado
3.3 TPM
Cérebro - Hemisfério cerebelar
2.7 TPM
Cerebelo
2.2 TPM
OUTRAS DOENÇAS (2)
pyruvate kinase hyperactivitypyruvate kinase deficiency of red cells
HGNC:9020UniProt:P30613
GRID2Glutamate receptor ionotropic, delta-2Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Member of the ionotropic glutamate receptor family, which plays a crucial role in synaptic organization and signal transduction in the central nervous system. Although it shares structural features with ionotropic glutamate receptors, does not bind glutamate as a primary ligand (PubMed:34936451). Promotes synaptogenesis and mediates the D-Serine-dependent long term depression signals and AMPA receptor endocytosis of cerebellar parallel fiber-Purkinje cell (PF-PC) synapses through the NRX1B-CBLN1

LOCALIZAÇÃO

Postsynaptic cell membrane

MECANISMO DE DOENÇA

Spinocerebellar ataxia, autosomal recessive, 18

A form of spinocerebellar ataxia, a clinically and genetically heterogeneous group of cerebellar disorders. Patients show progressive incoordination of gait and often poor coordination of hands, speech and eye movements, due to degeneration of the cerebellum with variable involvement of the brainstem and spinal cord. SCAR18 features include progressive cerebellar atrophy, delayed psychomotor development, severely impaired gait, ocular movement abnormalities, and intellectual disability.

EXPRESSÃO TECIDUAL(Tecido-específico)
Cerebelo
10.4 TPM
Cérebro - Hemisfério cerebelar
7.5 TPM
Testículo
6.2 TPM
Brain Nucleus accumbens basal ganglia
1.8 TPM
Hipotálamo
1.6 TPM
OUTRAS DOENÇAS (1)
autosomal recessive spinocerebellar ataxia 18
HGNC:4576UniProt:O43424
ALDH18A1Delta-1-pyrroline-5-carboxylate synthaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Bifunctional enzyme that converts glutamate to glutamate 5-semialdehyde, an intermediate in the biosynthesis of proline, ornithine and arginine

LOCALIZAÇÃO

MitochondrionMitochondrion matrix

VIAS BIOLÓGICAS (1)
Mitochondrial protein degradation
MECANISMO DE DOENÇA

Cutis laxa, autosomal recessive, 3A

A syndrome characterized by facial dysmorphism with a progeroid appearance, large and late-closing fontanel, cutis laxa, joint hyperlaxity, athetoid movements and hyperreflexia, pre- and postnatal growth retardation, intellectual deficit, developmental delay, and ophthalmologic abnormalities.

OUTRAS DOENÇAS (6)
hereditary spastic paraplegia 9Aautosomal recessive complex spastic paraplegia type 9Bcutis laxa, autosomal dominant 3ALDH18A1-related de Barsy syndrome
HGNC:9722UniProt:P54886
RAX2Retina and anterior neural fold homeobox protein 2Disease-causing germline mutation(s) inTolerante
FUNÇÃO

May be involved in modulating the expression of photoreceptor specific genes. Binds to the Ret-1 and Bat-1 element within the rhodopsin promoter

LOCALIZAÇÃO

Nucleus

MECANISMO DE DOENÇA

Macular degeneration, age-related, 6

A form of age-related macular degeneration, a multifactorial eye disease and the most common cause of irreversible vision loss in the developed world. In most patients, the disease is manifest as ophthalmoscopically visible yellowish accumulations of protein and lipid that lie beneath the retinal pigment epithelium and within an elastin-containing structure known as Bruch membrane.

EXPRESSÃO TECIDUAL(Baixa expressão)
Pituitária
1.9 TPM
Fallopian Tube
0.9 TPM
Útero
0.7 TPM
Cervix Endocervix
0.1 TPM
Testículo
0.1 TPM
OUTRAS DOENÇAS (4)
retinitis pigmentosa 95cone-rod dystrophy 11age related macular degeneration 6cone-rod dystrophy
HGNC:18286UniProt:Q96IS3
IFT140Intraflagellar transport protein 140 homologDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Component of the IFT complex A (IFT-A), a complex required for retrograde ciliary transport and entry into cilia of G protein-coupled receptors (GPCRs) (PubMed:20889716, PubMed:22503633). Plays a pivotal role in proper development and function of ciliated cells through its role in ciliogenesis and/or cilium maintenance (PubMed:22503633). Required for the development and maintenance of the outer segments of rod and cone photoreceptor cells. Plays a role in maintenance and the delivery of opsin to

LOCALIZAÇÃO

Cytoplasm, cytoskeleton, cilium basal bodyCytoplasm, cytoskeleton, microtubule organizing center, centrosomeCell projection, cilium

VIAS BIOLÓGICAS (2)
Hedgehog 'off' stateIntraflagellar transport
MECANISMO DE DOENÇA

Short-rib thoracic dysplasia 9 with or without polydactyly

A form of short-rib thoracic dysplasia, a group of autosomal recessive ciliopathies that are characterized by a constricted thoracic cage, short ribs, shortened tubular bones, and a 'trident' appearance of the acetabular roof. Polydactyly is variably present. Non-skeletal involvement can include cleft lip/palate as well as anomalies of major organs such as the brain, eye, heart, kidneys, liver, pancreas, intestines, and genitalia. Some forms of the disease are lethal in the neonatal period due to respiratory insufficiency secondary to a severely restricted thoracic cage, whereas others are compatible with life. Disease spectrum encompasses Ellis-van Creveld syndrome, asphyxiating thoracic dystrophy (Jeune syndrome), Mainzer-Saldino syndrome, and short rib-polydactyly syndrome. SRTD9 is characterized by phalangeal cone-shaped epiphyses, chronic renal disease, nearly constant retinal dystrophy, and mild radiographic abnormality of the proximal femur. Occasional features include short stature, cerebellar ataxia, and hepatic fibrosis.

EXPRESSÃO TECIDUAL(Ubíquo)
Tireoide
59.8 TPM
Testículo
47.9 TPM
Pituitária
34.4 TPM
Ovário
31.1 TPM
Cervix Endocervix
29.6 TPM
OUTRAS DOENÇAS (8)
retinitis pigmentosa 80cranioectodermal dysplasia 5short-rib thoracic dysplasia 9 with or without polydactylyJeune syndrome
HGNC:29077UniProt:Q96RY7
PCAREPhotoreceptor cilium actin regulatorDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Plays an essential role for normal photoreceptor cell maintenance and vision

LOCALIZAÇÃO

Cell projection, cilium, photoreceptor outer segmentPhotoreceptor inner segment

MECANISMO DE DOENÇA

Retinitis pigmentosa 54

A retinal dystrophy belonging to the group of pigmentary retinopathies. Retinitis pigmentosa is characterized by retinal pigment deposits visible on fundus examination and primary loss of rod photoreceptor cells followed by secondary loss of cone photoreceptors. Patients typically have night vision blindness and loss of midperipheral visual field. As their condition progresses, they lose their far peripheral visual field and eventually central vision as well.

OUTRAS DOENÇAS (2)
retinitis pigmentosa 54retinitis pigmentosa
HGNC:34383UniProt:A6NGG8
PRPF31U4/U6 small nuclear ribonucleoprotein Prp31Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Involved in pre-mRNA splicing as component of the spliceosome (PubMed:11867543, PubMed:20118938, PubMed:28781166). Required for the assembly of the U4/U5/U6 tri-snRNP complex, one of the building blocks of the spliceosome (PubMed:11867543)

LOCALIZAÇÃO

NucleusNucleus speckleNucleus, Cajal body

VIAS BIOLÓGICAS (1)
mRNA Splicing - Major Pathway
MECANISMO DE DOENÇA

Retinitis pigmentosa 11

A retinal dystrophy belonging to the group of pigmentary retinopathies. Retinitis pigmentosa is characterized by retinal pigment deposits visible on fundus examination and primary loss of rod photoreceptor cells followed by secondary loss of cone photoreceptors. Patients typically have night vision blindness and loss of midperipheral visual field. As their condition progresses, they lose their far peripheral visual field and eventually central vision as well.

EXPRESSÃO TECIDUAL(Ubíquo)
Cervix Endocervix
81.5 TPM
Útero
81.1 TPM
Fibroblastos
77.6 TPM
Linfócitos
76.5 TPM
Cervix Ectocervix
76.4 TPM
OUTRAS DOENÇAS (2)
retinitis pigmentosa 11retinitis pigmentosa
HGNC:15446UniProt:Q8WWY3
FDXRNADPH:adrenodoxin oxidoreductase, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Serves as the first electron transfer protein in all the mitochondrial P450 systems including cholesterol side chain cleavage in all steroidogenic tissues, steroid 11-beta hydroxylation in the adrenal cortex, 25-OH-vitamin D3-24 hydroxylation in the kidney, and sterol C-27 hydroxylation in the liver (By similarity). Also acts as a ferredoxin--NADP(+) reductase essential for coenzyme Q biosynthesis: together with FDX2, transfers the electrons required for the hydroxylation reaction performed by C

LOCALIZAÇÃO

MitochondrionMitochondrion inner membrane

VIAS BIOLÓGICAS (4)
Electron transport from NADPH to FerredoxinEndogenous sterolsPregnenolone biosynthesisDefective CYP11A1 causes AICSR
MECANISMO DE DOENÇA

Auditory neuropathy and optic atrophy

An autosomal recessive disease characterized by hearing loss, visual impairment and optic atrophy, with onset in the first or second decades of life. Optic atrophy is caused by degeneration of nerve fibers which arise in the retina and converge to form the optic disk, optic nerve, optic chiasm and optic tracts.

EXPRESSÃO TECIDUAL(Ubíquo)
Glândula adrenal
302.8 TPM
Testículo
77.8 TPM
Baço
43.0 TPM
Linfócitos
37.8 TPM
Ovário
37.6 TPM
OUTRAS DOENÇAS (3)
multiple mitochondrial dysfunctions syndrome 9bauditory neuropathy-optic atrophy syndromeoptic atrophy-ataxia-peripheral neuropathy-global developmental delay syndrome
HGNC:3642UniProt:P22570
MMUTMethylmalonyl-CoA mutase, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalyzes the reversible isomerization of methylmalonyl-CoA (MMCoA) (generated from branched-chain amino acid metabolism and degradation of dietary odd chain fatty acids and cholesterol) to succinyl-CoA (3-carboxypropionyl-CoA), a key intermediate of the tricarboxylic acid cycle

LOCALIZAÇÃO

Mitochondrion matrixMitochondrionCytoplasm

VIAS BIOLÓGICAS (3)
Cobalamin (Cbl) metabolismPropionyl-CoA catabolismDefective MMAA causes MMA, cblA type
MECANISMO DE DOENÇA

Methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency

An often fatal disorder of organic acid metabolism. Common clinical features include lethargy, vomiting, failure to thrive, hypotonia, neurological deficit and early death. Two forms of the disease are distinguished by the presence (mut-) or absence (mut0) of residual enzyme activity. Mut0 patients have more severe neurological manifestations of the disease than do MUT- patients. MAMM is unresponsive to vitamin B12 therapy.

OUTRAS DOENÇAS (3)
methylmalonic aciduria due to methylmalonyl-CoA mutase deficiencyvitamin B12-unresponsive methylmalonic acidemia type mut-vitamin B12-unresponsive methylmalonic acidemia type mut0
HGNC:7526UniProt:P22033
PRDX1Peroxiredoxin-1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Thiol-specific peroxidase that catalyzes the reduction of hydrogen peroxide and organic hydroperoxides to water and alcohols, respectively. Plays a role in cell protection against oxidative stress by detoxifying peroxides and as sensor of hydrogen peroxide-mediated signaling events. Might participate in the signaling cascades of growth factors and tumor necrosis factor-alpha by regulating the intracellular concentrations of H(2)O(2) (PubMed:9497357). Reduces an intramolecular disulfide bond in G

LOCALIZAÇÃO

CytoplasmMelanosome

VIAS BIOLÓGICAS (4)
TP53 Regulates Metabolic GenesNFE2L2 regulating anti-oxidant/detoxification enzymesDetoxification of Reactive Oxygen SpeciesDeregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models
EXPRESSÃO TECIDUAL(Ubíquo)
Esôfago - Mucosa
790.6 TPM
Tireoide
635.9 TPM
Linfócitos
598.5 TPM
Fibroblastos
487.5 TPM
Brain Spinal cord cervical c-1
472.8 TPM
OUTRAS DOENÇAS (1)
methylmalonic aciduria and homocystinuria type cblC
HGNC:HGNC:9352UniProt:Q06830
CELBile salt-activated lipaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalyzes the hydrolysis of a wide range of substrates including cholesteryl esters, phospholipids, lysophospholipids, di- and tri-acylglycerols, and fatty acid esters of hydroxy fatty acids (FAHFAs) (PubMed:10220579, PubMed:27509211, PubMed:27650499, PubMed:8471055). Preferentially hydrolyzes FAHFAs with the ester bond further away from the carboxylate. Unsaturated FAHFAs are hydrolyzed more quickly than saturated FAHFAs (By similarity). Has an essential role in the complete digestion of dietar

LOCALIZAÇÃO

Secreted

VIAS BIOLÓGICAS (1)
Developmental Lineage of Pancreatic Acinar Cells
MECANISMO DE DOENÇA

Maturity-onset diabetes of the young 8 with exocrine dysfunction

An autosomal dominant form of diabetes characterized by a primary defect in insulin secretion, exocrine pancreatic dysfunction, altered pancreatic morphology, recurrent abdominal pain, and fecal elastase deficiency. Disease onset is at less than 25 years of age.

OUTRAS DOENÇAS (2)
maturity-onset diabetes of the young type 8maturity-onset diabetes of the young
HGNC:1848UniProt:P19835
KLF11Krueppel-like factor 11Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Transcription factor (PubMed:10207080, PubMed:9748269). Activates the epsilon- and gamma-globin gene promoters and, to a much lower degree, the beta-globin gene and represses promoters containing SP1-like binding inhibiting cell growth (PubMed:10207080, PubMed:16131492, PubMed:9748269). Represses transcription of SMAD7 which enhances TGF-beta signaling (By similarity). Induces apoptosis (By similarity)

LOCALIZAÇÃO

Nucleus

MECANISMO DE DOENÇA

Maturity-onset diabetes of the young 7

A form of diabetes that is characterized by an autosomal dominant mode of inheritance, onset in childhood or early adulthood (usually before 25 years of age), a primary defect in insulin secretion and frequent insulin-independence at the beginning of the disease.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
43.6 TPM
Tecido adiposo
42.3 TPM
Adipose Visceral Omentum
38.4 TPM
Skin Not Sun Exposed Suprapubic
35.0 TPM
Mama
34.6 TPM
INTERAÇÕES PROTEICAS (5)
OUTRAS DOENÇAS (2)
maturity-onset diabetes of the young type 7maturity-onset diabetes of the young
HGNC:11811UniProt:O14901
PAX4Paired box protein Pax-4Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Plays an important role in the differentiation and development of pancreatic islet beta cells. Transcriptional repressor that binds to a common element in the glucagon, insulin and somatostatin promoters. Competes with PAX6 for this same promoter binding site. Isoform 2 appears to be a dominant negative form antagonizing PAX4 transcriptional activity

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (1)
Regulation of gene expression in endocrine-committed (NEUROG3+) progenitor cells
MECANISMO DE DOENÇA

Type 2 diabetes mellitus

A multifactorial disorder of glucose homeostasis caused by a lack of sensitivity to insulin. Affected individuals usually have an obese body habitus and manifestations of a metabolic syndrome characterized by diabetes, insulin resistance, hypertension and hypertriglyceridemia. The disease results in long-term complications that affect the eyes, kidneys, nerves, and blood vessels.

EXPRESSÃO TECIDUAL(Baixa expressão)
Testículo
1.3 TPM
Intestino delgado
0.3 TPM
Cólon transverso
0.2 TPM
Pâncreas
0.0 TPM
Linfócitos
0.0 TPM
OUTRAS DOENÇAS (4)
maturity-onset diabetes of the young type 9type 2 diabetes mellitusmaturity-onset diabetes of the youngdiabetes mellitus, ketosis-prone
HGNC:8618UniProt:O43316
HNF4AHepatocyte nuclear factor 4-alphaDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Transcriptional regulator which controls the expression of hepatic genes during the transition of endodermal cells to hepatic progenitor cells, facilitating the recruitment of RNA pol II to the promoters of target genes (PubMed:30597922). Activates the transcription of CYP2C38 (By similarity). Represses the CLOCK-BMAL1 transcriptional activity and is essential for circadian rhythm maintenance and period regulation in the liver and colon cells (PubMed:30530698)

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (2)
Nuclear Receptor transcription pathwayNephron development
MECANISMO DE DOENÇA

Maturity-onset diabetes of the young 1

A form of diabetes that is characterized by an autosomal dominant mode of inheritance, onset in childhood or early adulthood (usually before 25 years of age), a primary defect in insulin secretion and frequent insulin-independence at the beginning of the disease.

EXPRESSÃO TECIDUAL(Tecido-específico)
Fígado
55.4 TPM
Cólon transverso
33.0 TPM
Intestino delgado
30.7 TPM
Rim - Córtex
11.4 TPM
Pâncreas
5.6 TPM
OUTRAS DOENÇAS (7)
maturity-onset diabetes of the young type 1Fanconi renotubular syndrome 4 with maturity-onset diabetes of the youngmonogenic diabetesatypical Fanconi syndrome-neonatal hyperinsulinism syndrome
HGNC:5024UniProt:P41235
SUOXSulfite oxidase, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalyzes the oxidation of sulfite to sulfate, the terminal reaction in the oxidative degradation of sulfur-containing amino acids

LOCALIZAÇÃO

Mitochondrion intermembrane space

VIAS BIOLÓGICAS (1)
Sulfide oxidation to sulfate
MECANISMO DE DOENÇA

Sulfite oxidase deficiency, isolated

A life-threatening, autosomal recessive neurometabolic disorder characterized by severe neurological impairment. Classic ISOD manifests in the first few hours to days of life and is characterized by intractable seizures, feeding difficulties, rapidly progressive encephalopathy, microcephaly, and profound intellectual disability. Children usually die during the first few months of life. Mild ISOD manifests in infancy or early childhood and is characterized by ectopia lentis that is variably present, developmental delay and regression, movement disorder characterized by dystonia and choreoathetosis, ataxia, and rarely acute hemiplegia due to metabolic stroke.

EXPRESSÃO TECIDUAL(Ubíquo)
Glândula adrenal
29.7 TPM
Fígado
27.3 TPM
Ovário
25.5 TPM
Bladder
25.1 TPM
Tireoide
24.1 TPM
OUTRAS DOENÇAS (1)
isolated sulfite oxidase deficiency
HGNC:11460UniProt:P51687
THTyrosine 3-monooxygenaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalyzes the conversion of L-tyrosine to L-dihydroxyphenylalanine (L-Dopa), the rate-limiting step in the biosynthesis of catecholamines, dopamine, noradrenaline, and adrenaline. Uses tetrahydrobiopterin and molecular oxygen to convert tyrosine to L-Dopa (PubMed:15287903, PubMed:1680128, PubMed:17391063, PubMed:24753243, PubMed:34922205, PubMed:8528210, Ref.18). In addition to tyrosine, is able to catalyze the hydroxylation of phenylalanine and tryptophan with lower specificity (By similarity).

LOCALIZAÇÃO

Cytoplasm, perinuclear regionNucleusCell projection, axonCytoplasmCytoplasmic vesicle, secretory vesicle, synaptic vesicle

VIAS BIOLÓGICAS (1)
Catecholamine biosynthesis
MECANISMO DE DOENÇA

Segawa syndrome autosomal recessive

A form of DOPA-responsive dystonia presenting in infancy or early childhood. Dystonia is defined by the presence of sustained involuntary muscle contractions, often leading to abnormal postures. Some cases present with parkinsonian symptoms in infancy. Unlike all other forms of dystonia, it is an eminently treatable condition, due to a favorable response to L-DOPA.

EXPRESSÃO TECIDUAL(Tecido-específico)
Substância negra
45.8 TPM
Hipotálamo
14.1 TPM
Brain Caudate basal ganglia
5.4 TPM
Glândula adrenal
4.2 TPM
Brain Nucleus accumbens basal ganglia
3.6 TPM
OUTRAS DOENÇAS (1)
TH-deficient dopa-responsive dystonia
HGNC:11782UniProt:P07101
ARHGEF18Rho guanine nucleotide exchange factor 18Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Acts as a guanine nucleotide exchange factor (GEF) for RhoA GTPases. Its activation induces formation of actin stress fibers. Also acts as a GEF for RAC1, inducing production of reactive oxygen species (ROS). Does not act as a GEF for CDC42. The G protein beta-gamma (Gbetagamma) subunits of heterotrimeric G proteins act as activators, explaining the integrated effects of LPA and other G-protein coupled receptor agonists on actin stress fiber formation, cell shape change and ROS production. Requi

LOCALIZAÇÃO

CytoplasmCytoplasm, cytoskeletonCell membraneApical cell membrane

VIAS BIOLÓGICAS (1)
TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
MECANISMO DE DOENÇA

Retinitis pigmentosa 78

A form of retinitis pigmentosa, a retinal dystrophy belonging to the group of pigmentary retinopathies. Retinitis pigmentosa is characterized by retinal pigment deposits visible on fundus examination and primary loss of rod photoreceptor cells followed by secondary loss of cone photoreceptors. Patients typically have night vision blindness and loss of midperipheral visual field. As their condition progresses, they lose their far peripheral visual field and eventually central vision as well. RP78 inheritance is autosomal recessive.

OUTRAS DOENÇAS (2)
retinitis pigmentosa 78retinitis pigmentosa
HGNC:17090UniProt:Q6ZSZ5
KIZCentrosomal protein kizunaDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Centrosomal protein required for establishing a robust mitotic centrosome architecture that can endure the forces that converge on the centrosomes during spindle formation. Required for stabilizing the expanded pericentriolar material around the centriole

LOCALIZAÇÃO

Cytoplasm, cytoskeleton, microtubule organizing center, centrosomeCytoplasm, cytoskeleton, cilium basal body

MECANISMO DE DOENÇA

Retinitis pigmentosa 69

A retinal dystrophy belonging to the group of pigmentary retinopathies. Retinitis pigmentosa is characterized by retinal pigment deposits visible on fundus examination and primary loss of rod photoreceptor cells followed by secondary loss of cone photoreceptors. Patients typically have night vision blindness and loss of midperipheral visual field. As their condition progresses, they lose their far peripheral visual field and eventually central vision as well.

EXPRESSÃO TECIDUAL(Ubíquo)
Cólon sigmoide
60.4 TPM
Cervix Endocervix
50.2 TPM
Cervix Ectocervix
38.4 TPM
Ovário
36.5 TPM
Bladder
35.1 TPM
INTERAÇÕES PROTEICAS (1)
OUTRAS DOENÇAS (2)
retinitis pigmentosa 69retinitis pigmentosa
HGNC:15865UniProt:Q2M2Z5
SLC7A14Solute carrier family 7 member 14Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Imports 4-aminobutanoate (GABA) into lysosomes. May act as a GABA sensor that regulates mTORC2-dependent INS signaling and gluconeogenesis. The transport mechanism and substrate selectivity remain to be elucidated

LOCALIZAÇÃO

Lysosome membrane

MECANISMO DE DOENÇA

Retinitis pigmentosa 68

A retinal dystrophy belonging to the group of pigmentary retinopathies. Retinitis pigmentosa is characterized by retinal pigment deposits visible on fundus examination and primary loss of rod photoreceptor cells followed by secondary loss of cone photoreceptors. Patients typically have night vision blindness and loss of midperipheral visual field. As their condition progresses, they lose their far peripheral visual field and eventually central vision as well.

EXPRESSÃO TECIDUAL(Tecido-específico)
Cérebro - Hemisfério cerebelar
21.6 TPM
Cerebelo
15.0 TPM
Pituitária
14.2 TPM
Hipotálamo
9.8 TPM
Brain Spinal cord cervical c-1
9.2 TPM
INTERAÇÕES PROTEICAS (1)
OUTRAS DOENÇAS (2)
retinitis pigmentosa 68retinitis pigmentosa
HGNC:29326UniProt:Q8TBB6
ARL6ADP-ribosylation factor-like protein 6Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Involved in membrane protein trafficking at the base of the ciliary organelle. Mediates recruitment onto plasma membrane of the BBSome complex which would constitute a coat complex required for sorting of specific membrane proteins to the primary cilia (PubMed:20603001). Together with BBS1, is necessary for correct trafficking of PKD1 to primary cilia (By similarity). Together with the BBSome complex and LTZL1, controls SMO ciliary trafficking and contributes to the sonic hedgehog (SHH) pathway

LOCALIZAÇÃO

Cell projection, cilium membraneCytoplasm, cytoskeleton, cilium axonemeCytoplasm, cytoskeleton, cilium basal body

VIAS BIOLÓGICAS (1)
BBSome-mediated cargo-targeting to cilium
MECANISMO DE DOENÇA

Bardet-Biedl syndrome 3

A syndrome characterized by usually severe pigmentary retinopathy, early-onset obesity, polydactyly, hypogenitalism, renal malformation and intellectual disability. Secondary features include diabetes mellitus, hypertension and congenital heart disease. Bardet-Biedl syndrome inheritance is autosomal recessive, but three mutated alleles (two at one locus, and a third at a second locus) may be required for clinical manifestation of some forms of the disease.

OUTRAS DOENÇAS (5)
retinitis pigmentosa 55Bardet-Biedl syndrome 3retinitis pigmentosaBardet-Biedl syndrome
HGNC:13210UniProt:Q9H0F7
RHORhodopsinDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Photoreceptor required for image-forming vision at low light intensity (PubMed:7846071, PubMed:8107847). Required for photoreceptor cell viability after birth (PubMed:12566452, PubMed:2215617). Light-induced isomerization of the chromophore 11-cis-retinal to all-trans-retinal triggers a conformational change that activates signaling via G-proteins (PubMed:26200343, PubMed:28524165, PubMed:28753425, PubMed:8107847). Subsequent receptor phosphorylation mediates displacement of the bound G-protein

LOCALIZAÇÃO

MembraneCell projection, cilium, photoreceptor outer segment

VIAS BIOLÓGICAS (4)
OpsinsG alpha (i) signalling eventsThe canonical retinoid cycle in rods (twilight vision)Inactivation, recovery and regulation of the phototransduction cascade
MECANISMO DE DOENÇA

Retinitis pigmentosa 4

A retinal dystrophy belonging to the group of pigmentary retinopathies. Retinitis pigmentosa is characterized by retinal pigment deposits visible on fundus examination and primary loss of rod photoreceptor cells followed by secondary loss of cone photoreceptors. Patients typically have night vision blindness and loss of midperipheral visual field. As their condition progresses, they lose their far peripheral visual field and eventually central vision as well.

EXPRESSÃO TECIDUAL(Baixa expressão)
Brain Frontal Cortex BA9
0.5 TPM
Cerebelo
0.5 TPM
Cérebro - Hemisfério cerebelar
0.5 TPM
Córtex cerebral
0.5 TPM
Testículo
0.2 TPM
OUTRAS DOENÇAS (6)
retinitis pigmentosa 4fundus albipunctatuscongenital stationary night blindness autosomal dominant 1retinitis pigmentosa
HGNC:10012UniProt:P08100
USH2AUsherinDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Involved in hearing and vision as member of the USH2 complex. In the inner ear, required for the maintenance of the hair bundle ankle formation, which connects growing stereocilia in developing cochlear hair cells. In retina photoreceptors, the USH2 complex is required for the maintenance of periciliary membrane complex that seems to play a role in regulating intracellular protein transport

LOCALIZAÇÃO

Cell projection, stereocilium membraneSecreted

MECANISMO DE DOENÇA

Usher syndrome 2A

USH is a genetically heterogeneous condition characterized by the association of retinitis pigmentosa with sensorineural deafness. Age at onset and differences in auditory and vestibular function distinguish Usher syndrome type 1 (USH1), Usher syndrome type 2 (USH2) and Usher syndrome type 3 (USH3). USH2 is characterized by congenital mild hearing impairment with normal vestibular responses.

EXPRESSÃO TECIDUAL(Baixa expressão)
Testículo
1.2 TPM
Fígado
0.8 TPM
Cérebro - Hemisfério cerebelar
0.2 TPM
Cerebelo
0.2 TPM
Coração - Átrio
0.2 TPM
OUTRAS DOENÇAS (5)
retinitis pigmentosa 39Usher syndrome type 2AUsher syndromeretinitis pigmentosa
HGNC:12601UniProt:O75445
TOPORSE3 ubiquitin-protein ligase ToporsDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Functions as an E3 ubiquitin-protein ligase and as an E3 SUMO1-protein ligase. Probable tumor suppressor involved in cell growth, cell proliferation and apoptosis that regulates p53/TP53 stability through ubiquitin-dependent degradation. May regulate chromatin modification through sumoylation of several chromatin modification-associated proteins. May be involved in DNA damage-induced cell death through IKBKE sumoylation

LOCALIZAÇÃO

NucleusNucleus, PML body

VIAS BIOLÓGICAS (3)
SUMOylation of immune response proteinsSUMOylation of transcription cofactorsSUMOylation of SUMOylation proteins
MECANISMO DE DOENÇA

Retinitis pigmentosa 31

A retinal dystrophy belonging to the group of pigmentary retinopathies. Retinitis pigmentosa is characterized by retinal pigment deposits visible on fundus examination and primary loss of rod photoreceptor cells followed by secondary loss of cone photoreceptors. Patients typically have night vision blindness and loss of midperipheral visual field. As their condition progresses, they lose their far peripheral visual field and eventually central vision as well.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
31.6 TPM
Ovário
23.5 TPM
Fibroblastos
21.4 TPM
Fallopian Tube
18.9 TPM
Cérebro - Hemisfério cerebelar
18.9 TPM
OUTRAS DOENÇAS (3)
retinitis pigmentosa 31retinitis pigmentosaorofaciodigital syndrome type 6
HGNC:21653UniProt:Q9NS56
PCCAPropionyl-CoA carboxylase alpha chain, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

This is one of the 2 subunits of the biotin-dependent propionyl-CoA carboxylase (PCC), a mitochondrial enzyme involved in the catabolism of odd chain fatty acids, branched-chain amino acids isoleucine, threonine, methionine, and valine and other metabolites (PubMed:6765947, PubMed:8434582). Propionyl-CoA carboxylase catalyzes the carboxylation of propionyl-CoA/propanoyl-CoA to D-methylmalonyl-CoA/(S)-methylmalonyl-CoA (PubMed:10101253, PubMed:6765947, PubMed:8434582). Within the holoenzyme, the

LOCALIZAÇÃO

Mitochondrion matrix

VIAS BIOLÓGICAS (2)
Defective HLCS causes multiple carboxylase deficiencyBiotin transport and metabolism
MECANISMO DE DOENÇA

Propionic acidemia type I

Life-threatening disease characterized by episodic vomiting, lethargy and ketosis, neutropenia, periodic thrombocytopenia, hypogammaglobulinemia, developmental retardation, and intolerance to protein.

EXPRESSÃO TECIDUAL(Ubíquo)
Glândula adrenal
26.2 TPM
Rim - Córtex
18.4 TPM
Cérebro - Hemisfério cerebelar
16.5 TPM
Rim - Medula
16.4 TPM
Cólon transverso
14.4 TPM
OUTRAS DOENÇAS (1)
propionic acidemia
HGNC:8653UniProt:P05165
PHGDHD-3-phosphoglycerate dehydrogenaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalyzes the reversible oxidation of 3-phospho-D-glycerate to 3-phosphonooxypyruvate, the first step of the phosphorylated L-serine biosynthesis pathway. Also catalyzes the reversible oxidation of 2-hydroxyglutarate to 2-oxoglutarate and the reversible oxidation of (S)-malate to oxaloacetate

LOCALIZAÇÃO

VIAS BIOLÓGICAS (1)
Serine metabolism
MECANISMO DE DOENÇA

Phosphoglycerate dehydrogenase deficiency

An autosomal recessive inborn error of L-serine biosynthesis, clinically characterized by congenital microcephaly, psychomotor retardation, and seizures.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
83.1 TPM
Brain Spinal cord cervical c-1
50.3 TPM
Skin Not Sun Exposed Suprapubic
50.0 TPM
Glândula salivar
47.9 TPM
Testículo
45.6 TPM
OUTRAS DOENÇAS (2)
Neu-Laxova syndrome 1PHGDH deficiency
HGNC:8923UniProt:O43175
KCNJ11ATP-sensitive inward rectifier potassium channel 11Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Inward rectifier potassium channel that forms the pore of ATP-sensitive potassium channels (KATP), regulating potassium permeability as a function of cytoplasmic ATP and ADP concentrations in many different cells (PubMed:29286281, PubMed:34815345). Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it. Their voltage dependence is regulated by the concentration of extracellular potassium; as external potassium is

LOCALIZAÇÃO

Membrane

VIAS BIOLÓGICAS (6)
Ion homeostasisABC-family proteins mediated transportDefective ABCC9 causes CMD10, ATFB12 and Cantu syndromeDefective ABCC8 can cause hypo- and hyper-glycemiasRegulation of insulin secretion
MECANISMO DE DOENÇA

Hyperinsulinemic hypoglycemia, familial, 2

A form of hyperinsulinemic hypoglycemia, a clinically and genetically heterogeneous disorder characterized by inappropriate insulin secretion from the pancreatic beta-cells in the presence of low blood glucose levels. HHF2 is a common cause of persistent hypoglycemia in infancy. Unless early and aggressive intervention is undertaken, brain damage from recurrent episodes of hypoglycemia may occur. HHF2 inheritance can be autosomal dominant or autosomal recessive.

EXPRESSÃO TECIDUAL(Ubíquo)
Músculo esquelético
87.1 TPM
Cerebelo
37.4 TPM
Cérebro - Hemisfério cerebelar
36.8 TPM
Córtex cerebral
14.0 TPM
Brain Frontal Cortex BA9
13.9 TPM
OUTRAS DOENÇAS (12)
maturity-onset diabetes of the young type 13diabetes mellitus, permanent neonatal 2hyperinsulinemic hypoglycemia, familial, 2diabetes mellitus, transient neonatal, 3
HGNC:6257UniProt:Q14654
MLYCDMalonyl-CoA decarboxylase, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalyzes the conversion of malonyl-CoA to acetyl-CoA. In the fatty acid biosynthesis MCD selectively removes malonyl-CoA and thus assures that methyl-malonyl-CoA is the only chain elongating substrate for fatty acid synthase and that fatty acids with multiple methyl side chains are produced. In peroxisomes it may be involved in degrading intraperoxisomal malonyl-CoA, which is generated by the peroxisomal beta-oxidation of odd chain-length dicarboxylic fatty acids. Plays a role in the metabolic

LOCALIZAÇÃO

CytoplasmMitochondrion matrixPeroxisomePeroxisome matrix

VIAS BIOLÓGICAS (2)
Beta-oxidation of very long chain fatty acidsPeroxisomal protein import
MECANISMO DE DOENÇA

Malonyl-CoA decarboxylase deficiency

Autosomal recessive disease characterized by abdominal pain, chronic constipation, episodic vomiting, metabolic acidosis and malonic aciduria.

EXPRESSÃO TECIDUAL(Ubíquo)
Coração - Ventrículo esquerdo
13.3 TPM
Músculo esquelético
11.2 TPM
Coração - Átrio
10.1 TPM
Esôfago - Muscular
6.9 TPM
Esôfago - Junção
6.7 TPM
OUTRAS DOENÇAS (1)
malonic aciduria
HGNC:7150UniProt:O95822
PDX1Pancreas/duodenum homeobox protein 1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Activates insulin, somatostatin, glucokinase, islet amyloid polypeptide and glucose transporter type 2 gene transcription. Particularly involved in glucose-dependent regulation of insulin gene transcription. As part of a PDX1:PBX1b:MEIS2b complex in pancreatic acinar cells is involved in the transcriptional activation of the ELA1 enhancer; the complex binds to the enhancer B element and cooperates with the transcription factor 1 complex (PTF1) bound to the enhancer A element. Binds preferentiall

LOCALIZAÇÃO

NucleusCytoplasm, cytosol

VIAS BIOLÓGICAS (5)
Regulation of gene expression in beta cellsRegulation of gene expression in early pancreatic precursor cellsDevelopmental Lineage of Multipotent Pancreatic Progenitor CellsDevelopmental Lineage of Pancreatic Ductal CellsDevelopmental Lineage of Pancreatic Acinar Cells
MECANISMO DE DOENÇA

Pancreatic agenesis 1

A disease characterized by isolated hypoplasia or agenesis of the pancreas, pancreatic beta-cell failure resulting in neonatal insulin-dependent diabetes mellitus, and exocrine pancreatic insufficiency.

EXPRESSÃO TECIDUAL(Tecido-específico)
Pâncreas
9.2 TPM
Linfócitos
0.5 TPM
Testículo
0.2 TPM
Fígado
0.2 TPM
Estômago
0.1 TPM
OUTRAS DOENÇAS (6)
maturity-onset diabetes of the young type 4pancreatic agenesis 1pancreatic agenesismaturity-onset diabetes of the young
HGNC:6107UniProt:P52945
PRPH2Peripherin-2Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Essential for retina photoreceptor outer segment disk morphogenesis, may also play a role with ROM1 in the maintenance of outer segment disk structure (By similarity). Required for the maintenance of retinal outer nuclear layer thickness (By similarity). Required for the correct development and organization of the photoreceptor inner segment (By similarity)

LOCALIZAÇÃO

MembraneCell projection, cilium, photoreceptor outer segmentPhotoreceptor inner segment

MECANISMO DE DOENÇA

Retinitis pigmentosa 7

A retinal dystrophy belonging to the group of pigmentary retinopathies. Retinitis pigmentosa is characterized by retinal pigment deposits visible on fundus examination and primary loss of rod photoreceptor cells followed by secondary loss of cone photoreceptors. Patients typically have night vision blindness and loss of midperipheral visual field. As their condition progresses, they lose their far peripheral visual field and eventually central vision as well.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
9.3 TPM
Ovário
6.8 TPM
Cervix Ectocervix
5.7 TPM
Pituitária
5.3 TPM
Músculo esquelético
5.0 TPM
OUTRAS DOENÇAS (13)
retinitis pigmentosa 7vitelliform macular dystrophy 3fundus albipunctatuschoroidal dystrophy, central areolar 2
HGNC:9942UniProt:P23942
DNAJC12DnaJ homolog subfamily C member 12Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Probable co-chaperone that participates in the proper folding of biopterin-dependent aromatic amino acid hydroxylases, which include phenylalanine-4-hydroxylase (PAH), tyrosine 3-monooxygenase (TH) and peripheral and neuronal tryptophan hydroxylases (TPH1 and TPH2)

LOCALIZAÇÃO

Cytoplasm

MECANISMO DE DOENÇA

Hyperphenylalaninemia, mild, non-BH4-deficient

An autosomal recessive disorder characterized by increased serum phenylalanine, normal BH4 metabolism, and highly variable neurologic defects, including movement abnormalities and intellectual disability.

EXPRESSÃO TECIDUAL(Ubíquo)
Cérebro - Hemisfério cerebelar
94.7 TPM
Cerebelo
68.8 TPM
Pituitária
43.4 TPM
Glândula adrenal
36.3 TPM
Hipotálamo
30.1 TPM
INTERAÇÕES PROTEICAS (3)
OUTRAS DOENÇAS (1)
hyperphenylalaninemia due to DNAJC12 deficiency
HGNC:28908UniProt:Q9UKB3
MAT1AS-adenosylmethionine synthase isoform type-1Disease-causing germline mutation(s) inModerado
FUNÇÃO

Catalyzes the formation of S-adenosylmethionine from methionine and ATP. The reaction comprises two steps that are both catalyzed by the same enzyme: formation of S-adenosylmethionine (AdoMet) and triphosphate, and subsequent hydrolysis of the triphosphate

LOCALIZAÇÃO

VIAS BIOLÓGICAS (3)
MethylationSulfur amino acid metabolismMetabolism of ingested SeMet, Sec, MeSec into H2Se
MECANISMO DE DOENÇA

Methionine adenosyltransferase deficiency

An inborn error of metabolism resulting in isolated hypermethioninemia. Most patients have no clinical abnormalities, although some neurologic symptoms may be present in rare cases with severe loss of methionine adenosyltransferase activity.

EXPRESSÃO TECIDUAL(Tecido-específico)
Fígado
749.3 TPM
Pâncreas
17.2 TPM
Testículo
16.7 TPM
Skin Sun Exposed Lower leg
9.0 TPM
Skin Not Sun Exposed Suprapubic
6.5 TPM
OUTRAS DOENÇAS (1)
methionine adenosyltransferase deficiency
HGNC:6903UniProt:Q00266
ADKAdenosine kinaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Adenosine kinase that mediates the phosphorylation of the purine nucleoside adenosine at the 5' position in an ATP-dependent manner: catalyzes phosphorylation of both unmodified and modified adenosines (PubMed:21963049, PubMed:40840445, PubMed:6246102, PubMed:8577746, PubMed:9070863). Plays a key role in the detoxification of modified adenosines containing N(6)-methylated adenine (m6A) post-transcriptional modification (PubMed:40840445). Modified nucleosides are derived from the degradation of R

LOCALIZAÇÃO

Cytoplasm, cytosolNucleusCytoplasm

VIAS BIOLÓGICAS (2)
Purine salvageRibavirin ADME
MECANISMO DE DOENÇA

Hypermethioninemia due to adenosine kinase deficiency

A metabolic disorder characterized by global developmental delay, early-onset seizures, mild dysmorphic features, and characteristic biochemical anomalies, including persistent hypermethioninemia with increased levels of S-adenosylmethionine and S-adenosylhomocysteine. Homocysteine levels are typically normal.

OUTRAS DOENÇAS (1)
adenosine kinase deficiency
HGNC:257UniProt:P55263
CA5ACarbonic anhydrase 5A, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Mitochondrial carbonic anhydrase that catalyzes the reversible conversion of carbon dioxide to bicarbonate/HCO3 (PubMed:24530203, PubMed:8356065). Mitochondria are impermeable to HCO3, and thus this intramitochondrial carbonic anhydrase is pivotal in providing HCO3 for multiple mitochondrial enzymes that catalyze the formation of essential metabolites of intermediary metabolism in the urea and Krebs cycles (PubMed:24530203)

LOCALIZAÇÃO

Mitochondrion

VIAS BIOLÓGICAS (1)
Reversible hydration of carbon dioxide
MECANISMO DE DOENÇA

Hyperammonemia due to carbonic anhydrase VA deficiency

An autosomal recessive inborn error of metabolism, clinically characterized by infantile hyperammonemic encephalopathy. Metabolic abnormalities include hypoglycemia, hyperlactatemia, metabolic acidosis and respiratory alkalosis.

INTERAÇÕES PROTEICAS (2)
OUTRAS DOENÇAS (1)
hyperammonemic encephalopathy due to carbonic anhydrase VA deficiency
HGNC:1377UniProt:P35218

Variantes genéticas (ClinVar)

470 variantes patogênicas registradas no ClinVar.

🧬 BLOC1S3: GRCh38/hg38 19q13.31-13.32(chr19:44626066-46268105)x3 ()
🧬 BLOC1S3: NM_001382422.1(EXOC3L2):c.1999-138A>C ()
🧬 BLOC1S3: NM_212550.5(BLOC1S3):c.87dup (p.Ser30fs) ()
🧬 BLOC1S3: NM_212550.5(BLOC1S3):c.101C>A (p.Ser34Ter) ()
🧬 BLOC1S3: NM_212550.5(BLOC1S3):c.100_101inv (p.Ser34Glu) ()
Ver todas no ClinVar

Vias biológicas (Reactome)

158 vias biológicas associadas aos genes desta condição.

Golgi Associated Vesicle Biogenesis Amino acid transport across the plasma membrane Defective SLC3A1 causes cystinuria (CSNU) Defective SLC7A9 causes cystinuria (CSNU) Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation SLC-mediated transport of neurotransmitters Defective SLC6A19 causes Hartnup disorder (HND) Defective SLC6A19 causes Hartnup disorder (HND) Methylation Sulfur amino acid metabolism Defective MTRR causes HMAE Defective MTR causes HMAG Cobalamin (Cbl) metabolism Biotin transport and metabolism Defective HLCS causes multiple carboxylase deficiency Branched-chain amino acid catabolism 3-Methylcrotonyl-CoA carboxylase deficiency NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux Diseases of branched-chain amino acid catabolism PTEN Regulation Regulation of PTEN gene transcription FCERI mediated NF-kB activation TP53 Regulates Metabolic Genes Stabilization of p53 Defective RHAG causes regulator type Rh-null hemolytic anemia (RHN) Regulation of TP53 Activity through Phosphorylation TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway mRNA Splicing - Major Pathway mRNA Splicing - Minor Pathway Dengue Virus-Host Interactions BBSome-mediated cargo-targeting to cilium Respiratory electron transport Molybdenum cofactor biosynthesis Beta oxidation of decanoyl-CoA to octanoyl-CoA-CoA Defective MMADHC causes MMAHCD LDL clearance Translocation of SLC2A4 (GLUT4) to the plasma membrane Regulation of actin dynamics for phagocytic cup formation Insulin processing FCGR3A-mediated phagocytosis Regulation of MITF-M-dependent genes involved in pigmentation Protein lipoylation Recycling of bile acids and salts Signaling by Hippo Apoptotic cleavage of cell adhesion proteins RHOA GTPase cycle RHOB GTPase cycle RHOC GTPase cycle G alpha (q) signalling events Class C/3 (Metabotropic glutamate/pheromone receptors) Neurexins and neuroligins Sensory perception of sweet, bitter, and umami (glutamate) taste Tyrosine catabolism XBP1(S) activates chaperone genes Beta oxidation of palmitoyl-CoA to myristoyl-CoA Defective MMACHC causes MAHCC Regulation of pyruvate dehydrogenase (PDH) complex Signaling by Retinoic Acid Mitochondrial protein degradation PDH complex synthesizes acetyl-CoA from PYR Lanosterol biosynthesis Glutamate Neurotransmitter Release Cycle Defective SLC1A1 is implicated in schizophrenia 18 (SCZD18) and dicarboxylic aminoaciduria (DCBXA) SLC-mediated transport of amino acids Lysine catabolism Sodium/Calcium exchangers Defective SLC24A5 causes oculocutaneous albinism 6 (OCA6) Mitochondrial protein import Aspartate and asparagine metabolism Malate-aspartate shuttle Glutamate and glutamine metabolism Proline catabolism Tryptophan catabolism OADH complex synthesizes glutaryl-CoA from 2-OA ATP sensitive Potassium channels Regulation of insulin secretion Defective ABCC8 can cause hypo- and hyper-glycemias Degradation of GABA Processing of SMDT1 Mitochondrial iron-sulfur cluster biogenesis Maturation of TCA enzymes and regulation of TCA cycle Pyruvate metabolism Propionyl-CoA catabolism Defective MMAA causes MMA, cblA type Defective ABCD4 causes MAHCJ Uptake of dietary cobalamins into enterocytes Transport of RCbl within the body Transcriptional activation of mitochondrial biogenesis HATs acetylate histones UCH proteinases Formation of WDR5-containing histone-modifying complexes RUNX1 regulates transcription of genes involved in BCR signaling Antigen activates B Cell Receptor (BCR) leading to generation of second messengers Regulation of gene expression in beta cells Synthesis, secretion, and deacylation of Ghrelin COPI-mediated anterograde transport PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling IRS activation Signal attenuation Insulin receptor signalling cascade Signaling by Insulin receptor Insulin receptor recycling FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes NPAS4 regulates expression of target genes Amyloid fiber formation Urea cycle SLC25A15 variants cause hyperornithinemia-hyperammonemia-homocitrullinemia syndrome Glycine degradation ChREBP activates metabolic gene expression Glycolysis SARS-CoV-1-host interactions Hedgehog 'off' state Intraflagellar transport Pregnenolone biosynthesis Endogenous sterols Electron transport from NADPH to Ferredoxin Defective CYP11A1 causes AICSR Defective MUT causes MMAM Scavenging by Class B Receptors Detoxification of Reactive Oxygen Species Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models NFE2L2 regulating anti-oxidant/detoxification enzymes Digestion of dietary lipid Developmental Lineage of Pancreatic Acinar Cells Regulation of gene expression in endocrine-committed (NEUROG3+) progenitor cells Nuclear Receptor transcription pathway Nephron development Sulfide oxidation to sulfate Catecholamine biosynthesis NRAGE signals death through JNK TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) G alpha (12/13) signalling events RAC1 GTPase cycle Transphosphorylation of pLIMK1 The canonical retinoid cycle in rods (twilight vision) Activation of the phototransduction cascade Inactivation, recovery and regulation of the phototransduction cascade G alpha (i) signalling events Opsins VxPx cargo-targeting to cilium SUMOylation of transcription cofactors SUMOylation of SUMOylation proteins SUMOylation of immune response proteins Serine metabolism ABC-family proteins mediated transport Ion homeostasis Defective ABCC9 causes CMD10, ATFB12 and Cantu syndrome Beta-oxidation of very long chain fatty acids Peroxisomal protein import Regulation of gene expression in early pancreatic precursor cells Developmental Lineage of Pancreatic Ductal Cells Developmental Lineage of Multipotent Pancreatic Progenitor Cells CREB3L4 translocates from the cytosol to the nucleus Metabolism of ingested SeMet, Sec, MeSec into H2Se Defective MAT1A causes MATD Purine salvage Ribavirin ADME Reversible hydration of carbon dioxide

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Doença do metabolismo dos aminoácidos ou proteínas

Centros de Referência SUS

21 centros habilitados pelo SUS para Doença do metabolismo dos aminoácidos ou proteínas

Centros para Doença do metabolismo dos aminoácidos ou proteínas

Detalhes dos centros

Hospital Universitário Prof. Edgard Santos (HUPES)

R. Dr. Augusto Viana, s/n - Canela, Salvador - BA, 40110-060 · CNES 0003808

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo

Hospital de Apoio de Brasília (HAB)

AENW 3 Lote A Setor Noroeste - Plano Piloto, Brasília - DF, 70684-831 · CNES 0010456

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital Estadual Infantil e Maternidade Alzir Bernardino Alves (HIABA)

Av. Min. Salgado Filho, 918 - Soteco, Vila Velha - ES, 29106-010 · CNES 6631207

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital das Clínicas da UFG

Rua 235 QD. 68 Lote Área, Nº 285, s/nº - Setor Leste Universitário, Goiânia - GO, 74605-050 · CNES 2338424

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo

Hospital das Clínicas da UFMG

Av. Prof. Alfredo Balena, 110 - Santa Efigênia, Belo Horizonte - MG, 30130-100 · CNES 2280167

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

NUPAD / Faculdade de Medicina UFMG

Av. Prof. Alfredo Balena, 189 - 5 andar - Centro, Belo Horizonte - MG, 30130-100 · CNES 2183226

Serviço de Referência

Rota
Erros Inatos do Metabolismo

Hospital Universitário João de Barros Barreto

R. dos Mundurucus, 4487 - Guamá, Belém - PA, 66073-000 · CNES 2337878

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital de Clínicas da Universidade Federal de Pernambuco

Av. Prof. Moraes Rego, 1235 - Cidade Universitária, Recife - PE, 50670-901 · CNES 2561492

Atenção Especializada

Rota
Erros Inatos do Metabolismo

Instituto de Medicina Integral Prof. Fernando Figueira (IMIP)

R. dos Coelhos, 300 - Boa Vista, Recife - PE, 50070-902 · CNES 0000647

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital de Clínicas da UFPR

R. Gen. Carneiro, 181 - Alto da Glória, Curitiba - PR, 80060-900 · CNES 2364980

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital Universitário Pedro Ernesto (HUPE-UERJ)

Blvd. 28 de Setembro, 77 - Vila Isabel, Rio de Janeiro - RJ, 20551-030 · CNES 2280221

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo

Instituto Nacional de Saúde da Mulher, da Criança e do Adolescente Fernandes Figueira (IFF/Fiocruz)

Av. Rui Barbosa, 716 - Flamengo, Rio de Janeiro - RJ, 22250-020 · CNES 2269988

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital Universitário Onofre Lopes (HUOL)

Av. Nilo Peçanha, 620 - Petrópolis, Natal - RN, 59012-300 · CNES 2408570

Atenção Especializada

Rota
Erros Inatos do Metabolismo

Hospital São Lucas da PUCRS

Av. Ipiranga, 6690 - Jardim Botânico, Porto Alegre - RS, 90610-000 · CNES 2232928

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo

Hospital de Clínicas de Porto Alegre (HCPA)

Rua Ramiro Barcelos, 2350 Bloco A - Av. Protásio Alves, 211 - Bloco B e C - Santa Cecília, Porto Alegre - RS, 90035-903 · CNES 2237601

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital Universitário da UFSC (HU-UFSC)

R. Profa. Maria Flora Pausewang - Trindade, Florianópolis - SC, 88036-800 · CNES 2560356

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo

Hospital das Clínicas da FMUSP

R. Dr. Ovídio Pires de Campos, 225 - Cerqueira César, São Paulo - SP, 05403-010 · CNES 2077485

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital de Clínicas da UNICAMP

R. Vital Brasil, 251 - Cidade Universitária, Campinas - SP, 13083-888 · CNES 2748223

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital de Clínicas de Ribeirão Preto (HCRP-USP)

R. Ten. Catão Roxo, 3900 - Vila Monte Alegre, Ribeirão Preto - SP, 14015-010 · CNES 2082187

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Instituto da Criança e do Adolescente (ICr-HCFMUSP)

Av. Dr. Enéas Carvalho de Aguiar, 647 - Cerqueira César, São Paulo - SP, 05403-000 · CNES 2081695

Serviço de Referência

Rota
Erros Inatos do Metabolismo

UNIFESP / Hospital São Paulo

R. Napoleão de Barros, 715 - Vila Clementino, São Paulo - SP, 04024-002 · CNES 2688689

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo
Sobre os centros SUS: Estes centros são habilitados pelo Ministério da Saúde como Serviços de Referência em Doenças Raras ou Serviços de Atenção Especializada. O atendimento é pelo SUS, com encaminhamento da rede de atenção básica.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

Pesquisa e ensaios clínicos

Nenhum ensaio clínico registrado para esta condição.

🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
0 papers (10 anos)
#1

Expert consensus on the combined screening of genes and biomarkers for neonatal diseases.

World journal of pediatrics : WJP2026 Jan

Newborn screening (NBS) through disease biomarkers has significantly reduced severe outcomes of congenital disorders. Moreover, exploratory newborn genetic screening programs are increasingly being implemented. This consensus, developed by multidisciplinary experts, aims to standardize the combined screening of genes and biomarkers for neonatal diseases in China, balancing ethical, technical, and clinical considerations. This consensus synthesizes evidence from peer-reviewed literature (PubMed, CNKI, etc.) up to 2024 and integrates clinical experiences from multidisciplinary experts in neonatology, genetics, and laboratory medicine, focusing on disease biomarker-based NBS, newborn genetic screening, and the clinical utility of combined screening. The consensus defines principles for combined screening: (1) disease/gene selection: 154 disease-causing genes covering 67 inherited metabolic disorders (e.g., amino acid metabolism disorders, organic acid metabolism disorders), prioritized by treatability, onset age (< 5 years), and cost-effectiveness; (2) methodology: integrating dried blood spot biomarker analysis with next-generation sequencing-based targeted capture (coverage > 300 ×), validated by MLPA/Sanger and long-range sequencing for complex variants (e.g., CYP21A2, SLC25A13); and (3) operational workflow: standardized workflows for informed consent, sample collection/delivery, and result interpretation, with dual reporting of marker and genetic findings within 15 days. Positive cases require family verification and/or other genetic sequencing techniques. This consensus establishes a practical framework for integrating marker and genetic screening, aiming to improve diagnostic accuracy and achieve rapid and effective interventions, thereby saving lives and reducing the occurrence of severe complications. Implementation requires interdisciplinary collaboration and ongoing quality control to maximize clinical utility.

#2

Integrated pathological assessment and multi-omics analysis of the effects of Pinellia ternata aqueous extract on lung and spleen dysfunction in a rat model of phlegm-dampness obstruction.

Journal of ethnopharmacology2026 May 23

In traditional Chinese medicine (TCM), Pinellia ternata is widely used to treat respiratory and digestive disorders due to its efficacy in resolving phlegm, alleviating cough, and stopping nausea. Guided by the traditional concept that "the spleen generates phlegm and the lung stores it," this study established a sulfur-smoke combined with cold-damp exposure model in Sprague-Dawley rats to investigate the therapeutic effects and molecular mechanisms of P. ternata aqueous extract. Rats were assigned to blank (CK), model (MD), positive-drug (Y1/Y2), and low-, medium-, or high-dose P. ternata extract groups (0.75/1.5/3.0 g/kg). Lung function was assessed using a non-invasive Buxco system across 12 respiratory parameters. Lung and spleen pathology and mucin (MUC5AC/MUC5B) expression were evaluated by H&E staining and immunohistochemistry. Plasma IL-6, TNF-α, TGF-β, PCT, and other inflammatory markers were measured by ELISA. Plasma metabolite profiles were analyzed using LC-MS/GC-MS platforms, and lung and spleen transcriptomes were examined to determine gene expression changes. In parallel, the chemical constituents of the P.ternata aqueous extract were characterized using widely targeted metabolomics and high-performance liquid chromatography, and molecular docking was employed to elucidate the interactions between individual constituents and potential therapeutic targets. After 28 days of modeling, airway obstruction was most severe in the MD and low-dose extract groups, whereas the medium- and high-dose groups showed no significant difference from CK or the positive-drug groups, indicating effective symptom relief at adequate doses. The extract, especially at high dose, markedly improved lung and tracheal inflammation and restored spleen tissue architecture. It dose-dependently suppress MUC5AC overexpression in lung and tracheal tissues, while showing variable effects on MUC5B. The extract also reduced plasma pro-inflammatory cytokines and TGF-β and PCT levels, improving systemic immune imbalance. Metabolomics revealed that high-dose P.ternata downregulated amino acids related to mucin synthesis (e.g., proline) and inflammatory lysophosphatidylcholines, while increasing immune-regulatory lipids such as ω-3 PUFA and S1P. These metabolic shifts were accompanied by upregulation of key genes in the Notch pathway in the spleen and suppression of cytokine-storm-related signaling in the lung, including NF-κB(nuclear factor kappa-B), JAK-STAT(Janus kinase/signal transducer and activator of transcription), and PI3K-Akt(phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt)) signaling pathways, collectively reducing inflammation and correcting metabolic dysregulation. Combined targeted metabolomics and high-performance liquid chromatography identified that the major constituent categories in Pinellia ternata aqueous extract are organic acids, alkaloids, and nucleosides. Analysis of constituent-target interactions revealed that nucleoside compounds exhibited the strongest binding affinity to the predicted targets. This study, through integrated pathological, metabolomic, and transcriptomic analyses, elucidates both the core pathological features of phlegm-dampness lung obstruction and the modern biological basis for the traditional role of P. ternata in "strengthening the spleen and resolving phlegm." Importantly, nucleoside compounds were identified as key active constituents contributing to its therapeutic effects. Collectively, these findings offer experimental support for the classical TCM concept that spleen dysfunction leads to phlegm accumulation in the lung.

#3

Discovery of first-in-class melanostatin-based ago-allosteric modulators of the dopamine D2 receptors.

Biomedicine &amp; pharmacotherapy = Biomedecine &amp; pharmacotherapie2026 Mar

Melanostatin (MIF-1) is an endogenous tripeptide that acts as a positive allosteric modulator (PAM) of the dopamine D2 receptors (D2R), making it a valuable pharmacological lead for the treatment of dopamine-related disorders of the central nervous system (CNS). In this study, a novel series of MIF-1 derivatives was synthesized and pharmacologically evaluated to investigate the influence of ring flexibility and stereochemistry on PAM activity. For this purpose, the alicyclic β-amino acids (1R,2S)-2-aminocyclopentane-1-carboxylic acid (cispentacin) and its unsaturated precursor, (1R,2S)-2-aminocyclopent-3-ene-1-carboxylic acid, were used as proline surrogates. The results obtained showed that cispentacin-based derivatives 8b and 9b displayed PAM activity at 10 pM, significantly reducing the EC50 of dopamine by 4.34- and 4.22-fold, respectively (8b: EC50 = 20.08 ± 3.95 nM; 9b: EC50 = 20.61 ± 4.60 nM). At 1 nM, 8b further decreased the EC50 of dopamine by 9.20-fold (EC50 = 9.47 ± 5.02 nM) and, at higher concentrations (10 and 100 μM), it activated the D2R in the absence of dopamine, representing the first-in-class MIF-1-based ago-allosteric modulator of the D2R. Cytotoxicity assays in human dopaminergic-differentiated SH-SY5Y cells showed that neither 8b nor 9b exhibited cytotoxic effects at 100 μM, as assessed by both the MTT reduction and neutral red uptake assays, supporting their favorable toxicological profiles. Overall, these findings demonstrate that a fine-tuned interplay between ring flexibility and stereochemistry is a key determinant in generating effective PAM of the D2R, providing a framework for the future design of MIF-1-based modulators targeting Parkinson's disease and other dopamine-related CNS disorders. 3-Hydroxyisobutyryl-CoA hydrolase (HIBCH) deficiency can be categorized into three subtypes based on age of presentation. Neonatal onset, the least frequent phenotype, is characterized by hypotonia, seizures, and feeding difficulties at birth. There is a high risk of death in childhood, and individuals that survive typically have developmental delay, seizures, poor weight gain, and growth deficiency and develop a movement disorder. Infantile onset is the most common phenotype, presenting in the first two years of life with feeding difficulties, vomiting, developmental delay with regression, hypotonia, seizures, movement disorder, microcephaly, vision impairment, and episodes of neurologic deterioration. Late onset is the second most common phenotype, presenting in childhood as a slowly progressive disease with significant movement disorder with or without paroxysmal dystonia, variable cognitive impairment, and high survivability. The diagnosis of HIBCH deficiency is established in a proband with characteristic clinical, laboratory, and brain imaging findings and biallelic pathogenic variants in HIBCH identified by molecular genetic testing. Targeted therapy: Valine-restricted diet. As seen in other metabolic disorders, treatment using special formulas (medical food) can be implemented successfully via oral route in individuals diagnosed within the first few months of life. Later on, if palatability or feeding intolerance becomes a problem, formula can be given by gastrostomy tube. A restriction in total protein intake without quantitation of valine may be necessary in individuals on an oral diet with poor adherence to medical food or formula. Supportive care: Developmental and educational support; feeding therapy with gastrostomy tube as needed; standard treatments for spasticity and epilepsy; treatment of movement disorder per movement disorder specialist; management of ocular issues per ophthalmologist with low vision services as needed; early intervention for cerebral visual impairment; hearing aids per otolaryngologist and community hearing services as needed; transitional care support; social work and family support. Surveillance: Evaluation with a metabolic specialist and metabolic dietitian including assessment of total protein and valine intake, fasting plasma amino acids, blood total and free carnitine and acylcarnitine profile, lactic acid in blood, and urine organic acids with frequency per metabolic specialist; measurement of growth parameters, evaluation of nutrition and oral intake, and assessment of developmental progress and educational needs at each visit; assessment for changes in tone, seizures, movement disorders, mobility, self-help skills, evidence of aspiration, respiratory insufficiency, and sleep apnea at each visit; ophthalmology evaluation at least annually; audiology evaluation as needed. Agents/circumstances to avoid: Due to secondary mitochondrial abnormalities it may be beneficial to avoid sodium valproate if possible; consider anesthesia use carefully; avoid prolonged propofol use; prevent catabolism; avoid neuromuscular blocking agents in those with muscle disease; avoid lactate-containing agents, including dialysate containing lactate; ketogenic / modified Atkins diets should be avoided due to potential side effects; triheptanoin is contraindicated due to the potential increase in propionyl-CoA; dichloroacetate, as there is no published evidence to support its use in HIBCH deficiency. Evaluation of relatives at risk: It is appropriate to evaluate at-risk newborns and older sibs of an affected individual to identify as early as possible those who would benefit from prompt initiation of targeted therapy. HIBCH deficiency is inherited in an autosomal recessive manner. If both parents are known to be heterozygous for an HIBCH pathogenic variant, each sib of an affected individual has at conception a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. Once the HIBCH pathogenic variants have been identified in an affected family member, carrier testing for at-risk relatives and prenatal/preimplantation genetic testing are possible.

#4

Ileal Bile Acid Transporter Inhibitors in Cholestasis: Potential for More Than Just Paediatrics?

Liver international : official journal of the International Association for the Study of the Liver2026 Mar

Ileal bile acid transporter inhibitors (IBATi) are a new, attractive therapeutic mechanism to alter the enterohepatic circulation through depletion of the bile acid pool by blocking bile acid reuptake in the ileum leading to improvements in pruritus and liver function in cholestatic liver diseases. These drugs may also have an impact on immunity, the gut microbiome, and motility. IBATi are approved in Japan for the treatment of idiopathic chronic constipation. There are two IBATi, maralixibat and odevixibat, that have been extensively investigated in clinical trials and are FDA approved for cholestatic pruritus in progressive familial intrahepatic cholestasis and Alagille syndrome. Clinical trials exploring IBATi in other cholestatic conditions, such as biliary atresia, primary biliary cholangitis, and primary sclerosing cholangitis, are currently ongoing. In this review, we will outline the emerging data regarding the physiology and mechanism of action for the IBATi class, an overview of clinical trials that led to the approval of maralixibat and odevixibat, ongoing clinical trials in adult cholestatic liver diseases, and the future of this drug class in systemic apical sodium bile acid transporter inhibitors.

#5

Targeting cholinesterases with steroid hormone derivatives: Insights from In Vitro assays and molecular modeling.

The Journal of steroid biochemistry and molecular biology2026 Apr

Steroids represent a large family of organic compounds that, as signaling molecules, play important role in variety of physiological processes as control of metabolic pathways, inflammation processes, immune response, and growth, development and reproduction. Modifying the steroid core has allowed the creation of novel synthetic derivatives, which can offer significant benefits in medicine for treating a wide range of pathological conditions. Quite a number of natural steroids have been identified as effective inhibitors of cholinesterases, pointing them out as potential therapeutic alternatives in the application in Alzheimer's disease (AD). Nevertheless, only a limited number of synthetic steroids have so far been studied as cholinesterase inhibitors, highlighting an opportunity for the development of new therapeutic agents derived from natural steroidal frameworks. In this study, we selected a set of structurally diverse steroid hormone derivatives and evaluated in vitro their inhibitory activity against human AChE and BChE. IC50 values were estimated for several of the most active compounds, with pyridine-containing hydroxy derivative 8 exhibiting affinity toward BChE (IC50 2.76 µM), similar to that for clinically used cholinesterase inhibitors. In silico analyses suggest that hydrophobic interactions with key amino-acid residues predominantly govern the binding of these compounds within the enzyme's active site.

Publicações recentes

Ver todas no PubMed

📚 EuropePMCmostrando 199

2026

Integrated pathological assessment and multi-omics analysis of the effects of Pinellia ternata aqueous extract on lung and spleen dysfunction in a rat model of phlegm-dampness obstruction.

Journal of ethnopharmacology
2026

Discovery of first-in-class melanostatin-based ago-allosteric modulators of the dopamine D2 receptors.

Biomedicine &amp; pharmacotherapy = Biomedecine &amp; pharmacotherapie
2026

Ileal Bile Acid Transporter Inhibitors in Cholestasis: Potential for More Than Just Paediatrics?

Liver international : official journal of the International Association for the Study of the Liver
2026

Targeting cholinesterases with steroid hormone derivatives: Insights from In Vitro assays and molecular modeling.

The Journal of steroid biochemistry and molecular biology
2026

[Metabolic characteristics of the healthy scalp microenvironment based on spatial metabolomics and its comparison with psoriatic lesions].

Zhonghua yi xue za zhi
2025

Metabolomic analysis of synovial fluid from healthy and pathological equine joints and tendon sheaths using high-resolution 1H Nuclear Magnetic Resonance.

Frontiers in veterinary science
2026

Expert consensus on the combined screening of genes and biomarkers for neonatal diseases.

World journal of pediatrics : WJP
2026

Biochemical and structural insights of a new endolysin encoded by the Xanthomonas citri lytic phage CP2.

International journal of biological macromolecules
2026

Quantitative profiling of aromatic amino acids and their host-microbial co-metabolites in human urine via UPLC-MS/MS.

Journal of chromatography. A
2026

Biocontrol efficiency and mechanism of novel Streptomyces luomodiensis SCA4-21 against banana Fusarium wilt.

Microbiology spectrum
2025

Neurotropic Effects In Vivo of New Tryptamino-Triazines Compared to GABA Effectors.

ACS chemical neuroscience
2025

Transcriptome analysis of different developmental stages of Tilletia controversa revealed Chitin synthases genes for growth.

Current research in microbial sciences
2025

Transcriptomic and Metabolomic Mechanisms Underlying Adaptive Differentiation of Black Soldier Fly Larvae Induced by Regional Food Waste Domestication.

Biology
2026

The Arabidopsis neutral amino acid transporter UmamiT20 confers Botrytis cinerea susceptibility.

Journal of experimental botany
2025

Endothelial responses to angiogenic modulators highlight metabolic mechanisms underlying vascular dysfunction in preeclampsia.

Placenta
2026

The smell of Panulirus argus virus 1 (PaV1) infection: Disease-induced changes in metabolites in urine and hemolymph of Caribbean spiny lobsters Panulirus argus.

Journal of invertebrate pathology
2025

Biocontrol Activity of Volatile Organic Compounds Emitted from Bacillus paralicheniformis 2-12 Against Fusarium oxysporum Associated with Astragalus membranaceus Root Rot.

Microorganisms
2025

Engineering biology and chemical approaches to the construction of vitamin B12 analogues and antivitamins B12 as probes and therapeutic agents.

Advances in microbial physiology
2025

Blood metabolome of cardiovascular disease, diabetic kidney disease, and diabetic retinopathy in type 2 diabetes patients: A systematic review and meta-analysis.

Endocrine research
2025

DeepSecMS Advances DIA-Based Selenoproteome Profiling Through Cys-to-Sec Proxy Training.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)
2025

Delayed Diagnosis of Glutaric Aciduria Type 1: A Case Report.

Cureus
2025

Effects of 1-N-Naphthylphthalamic Acid on Root and Leaf Development of Muscari armeniacum and the Related Metabolic and Physiological Features.

International journal of molecular sciences
2025

Usefulness of levels of 2-methylbutyrylglycine and 2-ethylhydracrylic acid in urine for diagnosing 2-methylbutyrylglycinuria.

Orphanet journal of rare diseases
2025

Longan Arillus: A comprehensive review of botany, traditional uses, phytochemistry, pharmacologic activities, pharmacokinetics, quality control, toxicity, and clinical applications.

Journal of ethnopharmacology
2025

A Paper Strip-Based Photoinduced Electrogenerated Chemiluminescence Platform with CTF/PMo12 Heterojunction-Sensitive Glutamic Acid Detection.

Analytical chemistry
2025

Discovery of antiepileptic Q-Markers for Bombyx batryticatus: Integrating serum pharmacochemistry, network pharmacology and temporal-efficacy validation.

Journal of ethnopharmacology
2025

[Mechanism of Xiangmei Pills in treating ulcerative colitis based on UHPLC-Q-Orbitrap HRMS and 16S rDNA sequencing of intestinal flora].

Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica
2025

Analytical workflow for comprehensive blood metabolomics analysis by GC-MS. Application to children with ventilator associated pneumonia.

Journal of chromatography. A
2025

Donor-acceptor covalent organic framework nanofilm-based laser desorption/ionization mass spectrometry for rapid and sensitive determination of creatinine in human serum.

The Analyst
2025

Characterization of POP mixture redistribution and identification of their molecular signature in xenografted fat mice.

Environmental pollution (Barking, Essex : 1987)
2025

The diagnosis and treatment of disorders of nucleic acid/nucleotide metabolism associated with epilepsy.

Acta epileptologica
2025

A review on bacteria-derived antioxidant metabolites: their production, purification, characterization, potential applications, and limitations.

Archives of pharmacal research
2025

Zinc amino acid chelate and the Aryl Hydrocarbon Receptor (AHR) cooperate in improving the barrier function of a Caco-2 cell intestinal epithelium.

The Journal of nutritional biochemistry
2025

Deciphering the effective components of a TCM formula for atherosclerosis by three-dimensional pattern recognition of exogenous components correlated with endogenous metabolites.

Journal of ethnopharmacology
2025

Dynamic Metabolite Profile Changes in Semen Ziziphi Spinosae During Ripening.

Rapid communications in mass spectrometry : RCM
2025

Serum metabolic signatures and MetalnFF diagnostic score for mild and moderate metabolic dysfunction-associated steatotic liver disease.

Journal of pharmaceutical and biomedical analysis
2025

Zinc Glycine supplementation improves bone quality in meat geese by modulating gut microbiota, SCFA's, and gut barrier function through Wnt10b/NF-κB axis.

Poultry science
2025

Comprehensive tissue homogenization and metabolite extraction for application in clinical metabolomics.

Analytica chimica acta
2025

Human Milk Feeding in Inherited Metabolic Disorders: A Systematic Review of Growth, Metabolic Control, and Neurodevelopment Outcomes.

Journal of inherited metabolic disease
2025

C-terminal amides mark proteins for degradation via SCF-FBXO31.

Nature
2025

Mechanism study on the enhancement of bile acid-binding capacity in corn by-product juice via Lactiplantibacillus plantarum HY127 fermentation.

Food chemistry: X
2025

Urinary metabolic alterations associated with occupational exposure to metals and polycyclic aromatic hydrocarbons based on non-target metabolomics.

Journal of hazardous materials
2025

Breath biopsy in inborn errors of metabolism: A proof-of-principle study in propionic acidemia.

Molecular genetics and metabolism
2025

Monitoring Addiction to Pregabalin in Northern Algeria by Using Hair Testing.

Electrophoresis
2024

Inhibition of Accumulation of Neutral Lipids and Their Hydroperoxide Species in Hepatocytes by Bioactive Allium sativum Extract.

Antioxidants (Basel, Switzerland)
2025

Amyloid inspired single amino acid (phenylalanine)-based supramolecular functional assemblies: from disease to device applications.

Chemical Society reviews
2024

Determining the Reference Range of Amino Acids in Healthy Neonatal Blood Samples in Northeast Iran Using LC-MS/MS.

Reports of biochemistry &amp; molecular biology
2024

Banxia-Yiyiren alleviates insomnia and anxiety by regulating the gut microbiota and metabolites of PCPA-induced insomnia model rats.

Frontiers in microbiology
2025

Inhalation exposure to cross-linked polyacrylic acid induces pulmonary disorders.

Toxicology
2024

Improving methylmalonic acidemia (MMA) screening and MMA genotype prediction using random forest classifier in two Chinese populations.

European journal of medical research
2024

Serum metabolome alterations in hyperhomocysteinemia based on targeted and non-targeted MS-platforms.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences
2025

Based on Serum Pharmacochemistry and Metabolomics Studied the Pharmacodynamic Material Basis and Mechanism of Rubi Fructus (Fupenzi) in Improving the Symptom of Kidney-Yang Deficiency.

Chemistry &amp; biodiversity
2024

Development of a signs and symptoms outcome measure for caregivers of patients with methylmalonic acidemia and propionic acidemia (MMAPAQ).

Molecular genetics and metabolism
2024

Prediction of inherited metabolic disorders using tandem mass spectrometry data with the help of artificial neural networks.

Turkish journal of medical sciences
2024

Effect of a thiohydantoin salt derived from l-Arginine on Leishmania amazonensis and infected cells: Insights from biological effects to molecular docking interactions.

Chemico-biological interactions
2024

Glutaric Aciduria Presenting With an Acute Encephalitic Crisis: A Case Report.

Cureus
2024

The PARP inhibitor rucaparib blocks SARS-CoV-2 virus binding to cells and the immune reaction in models of COVID-19.

British journal of pharmacology
2025

Mass spectrometry (MS)-based metabolomics of plasma and urine in dry eye disease (DED)-induced rat model.

Journal of toxicology and environmental health. Part A
2024

Pathological characteristics of axons and alterations of proteomic and lipidomic profiles in midbrain dopaminergic neurodegeneration induced by WDR45-deficiency.

Molecular neurodegeneration
2024

Physiological disorders in cold-stored 'Autumn Sense' hardy kiwifruit depend on the storage temperature and the modulation of targeted metabolites.

Food chemistry
2025

Combined clinical, structural and cellular studies discriminate pathogenic and benign TRPV4 variants.

Brain : a journal of neurology
2024

The therapeutic landscape of citrin deficiency.

Journal of inherited metabolic disease
2024

The effects of Ganoderma leucocontextum triterpenoids treatment on the D-galactose and aluminum chloride-induced Alzheimer-like pathology in mouse brain.

Journal of ethnopharmacology
2024

Anti-hyperuricemia effect of Clerodendranthus spicatus: a molecular biology study combined with metabolomics.

Scientific reports
2024

Insights into the dynamic interactions of RNase a and osmolytes through computational approaches.

Journal of biomolecular structure &amp; dynamics
2024

Exploiting the roles of nitrogen sources for HEA increment in Cordyceps cicadae.

Frontiers in microbiology
2024

NMR Spectroscopy in Diagnosis and Monitoring of Methylmalonic and Propionic Acidemias.

Biomolecules
2024

Metabolomic pattern associated with physical sequelae in patients presenting with respiratory symptoms validates the aestivation concept in dehydrated patients.

Physiological genomics
2024

Targeted metabolomics combined with machine learning to identify and validate new biomarkers for early SLE diagnosis and disease activity.

Clinical immunology (Orlando, Fla.)
2024

Ginkgo biloba and Its Chemical Components in the Management of Alzheimer's Disease.

The American journal of Chinese medicine
2024

[Newborn screening in France: news and perspectives].

Annales de biologie clinique
2024

pH-sensitive release of nitric oxide gas using peptide-graphene co-assembled hybrid nanosheets.

Nitric oxide : biology and chemistry
2024

Extensive targeted metabolomics analysis reveals the identification of major metabolites, antioxidants, and disease-resistant active pharmaceutical components in Camellia tuberculata (Camellia L.) seeds.

Scientific reports
2024

Hepatobiliary circulation and dominant urinary excretion of homogentisic acid in a mouse model of alkaptonuria.

Journal of inherited metabolic disease
2024

Chemical synthesis of site-selective advanced glycation end products in α-synuclein and its fragments.

Organic &amp; biomolecular chemistry
2024

Rice-Magnaporthe oryzae interactions in resistant and susceptible rice cultivars under panicle blast infection based on defense-related enzyme activities and metabolomics.

PloS one
2024

Evaluation of Antitumor Activity of Xanthones Conjugated with Amino Acids.

International journal of molecular sciences
2024

Low molecular weight acids and OATP1B mediated hepatic clearance: In vitro and in vivo evaluation using novel hypoxia-inducible factor prolyl hydroxylase inhibitors (Dustats).

Drug metabolism and disposition: the biological fate of chemicals
2024

Parallel Metabolomics and Lipidomics of a PSMA/GCPII Deficient Mouse Model Reveal Alteration of NAAG Levels and Brain Lipid Composition.

ACS chemical neuroscience
2024

Integrated network pharmacology, metabolomics, and transcriptomics of Huanglian-Hongqu herb pair in non-alcoholic fatty liver disease.

Journal of ethnopharmacology
2023

Selective screening for inborn errors of metabolism using tandem mass spectrometry in West Kazakhstan children: study protocol.

Frontiers in genetics
2024

Dual-emissive europium doped UiO-66-based ratiometric light-up biosensor for highly sensitive detection of histidinemia biomarker.

Analytica chimica acta
2024

Aminoacylase 1 deficiency: case report on three affected siblings.

AME case reports
2023

Aluminum Supplementation Mediates the Changes in Tea Plant Growth and Metabolism in Response to Calcium Stress.

International journal of molecular sciences
2024

Shank3 Deficiency Results in a Reduction in GABAergic Postsynaptic Puncta in the Olfactory Brain Areas.

Neurochemical research
2023

Characterization of Metabolite Landscape Distinguishes Medicinal Fungus Cordyceps sinensis and other Cordyceps by UHPLC-Q Exactive HF-X Untargeted Metabolomics.

Molecules (Basel, Switzerland)
2023

Phenylalanine-based fibrillar systems.

Chemical communications (Cambridge, England)
2023

Gamma-Aminobutyric Acid Accumulation Contributes to Citrus sinensis Response against 'Candidatus Liberibacter Asiaticus' via Modulation of Multiple Metabolic Pathways and Redox Status.

Plants (Basel, Switzerland)
2023

Global Proteome-Wide Analysis of Cysteine S-Nitrosylation in Toxoplasma gondii.

Molecules (Basel, Switzerland)
2023

Dynamics and ecological reassembly of the human gut microbiome and the host metabolome in response to prolonged fasting.

Frontiers in microbiology
2023

Toxicity of decabromodiphenyl ethane on lettuce: Evaluation through growth, oxidative defense, microstructure, and metabolism.

Environmental pollution (Barking, Essex : 1987)
2024

Evaluation of the Neuroprotective Effect of Organic Selenium Compounds: An in Vitro Model of Alzheimer's Disease.

Biological trace element research
2024

Amino acid ratio combinations as biomarkers for discriminating patients with pyruvate dehydrogenase complex deficiency from other inborn errors of metabolism.

Molecular genetics &amp; genomic medicine
2023

Glutaryl-CoA Dehydrogenase Misfolding in Glutaric Acidemia Type 1.

International journal of molecular sciences
2023

Metabolic Differences in Diabetic Kidney Disease Patients with Normoalbuminuria versus Moderately Increased Albuminuria.

Kidney360
2023

High genetic heterogeneity of leukodystrophies in Iranian children: the first report of Iranian Leukodystrophy Registry.

Neurogenetics
2023

Nontoxic Levels of Se-Containing Compounds Increase Survival by Blocking Oxidative and Inflammatory Stresses via Signal Pathways Whereas High Levels of Se Induce Apoptosis.

Molecules (Basel, Switzerland)
2023

Newborn screening of maple syrup urine disease and the effect of early diagnosis.

Clinica chimica acta; international journal of clinical chemistry
2023

Vitamin B2 enables regulation of fasting glucose availability.

eLife
2023

Improvement effect of biochar on soil microbial community structure and metabolites of decline disease bayberry.

Frontiers in microbiology
2023

Pathological characteristics of axons and proteome patterns in midbrain dopaminergic neurodegeneration induced by WDR45-deficiency.

Research square
2023

Tuberculosis is associated with sputum metabolome variations, irrespective of patient sex or HIV status: an untargeted GCxGC-TOFMS study.

Metabolomics : Official journal of the Metabolomic Society
2023

Aspartate-glutamate carrier 2 (citrin): a role in glucose and amino acid metabolism in the liver.

BMB reports
2023

Challenges and strategies for clinical trials in propionic and methylmalonic acidemias.

Molecular genetics and metabolism
2023

Biomarkers to predict disease progression and therapeutic response in isolated methylmalonic acidemia.

Journal of inherited metabolic disease
2023

Engineered Synthetic STxB for Enhanced Cytosolic Delivery.

Cells
2023

New insights into the pathophysiology of methylmalonic acidemia.

Journal of inherited metabolic disease
2023

NAGS, CPS1, and SLC25A13 (Citrin) at the Crossroads of Arginine and Pyrimidines Metabolism in Tumor Cells.

International journal of molecular sciences
2023

Metabolic pathways altered by air pollutant exposure in association with lipid profiles in young adults.

Environmental pollution (Barking, Essex : 1987)
2023

Metabolomic Analysis of Respiratory Epithelial Lining Fluid in Patients with Chronic Obstructive Pulmonary Disease-A Systematic Review.

Cells
2023

Chemical Synthesis of Alpha-Synuclein Proteins via Solid-Phase Peptide Synthesis and Native Chemical Ligation.

Chemistry (Weinheim an der Bergstrasse, Germany)
2023

Unravelling inclusion body myositis using a patient-derived fibroblast model.

Journal of cachexia, sarcopenia and muscle
2023

Laboratory and metabolic investigations.

Handbook of clinical neurology
2023

Rapid and Quantitative Enrichment of Peptides from Plasma for Mass Spectrometric Analysis.

Methods in molecular biology (Clifton, N.J.)
2022

Chemically diverse activity-based probes with unexpected inhibitory mechanisms targeting trypsin-like serine proteases.

Frontiers in chemistry
2022

Comprehensive metabolomics and lipidomics profiling uncovering neuroprotective effects of Ginkgo biloba L. leaf extract on Alzheimer's disease.

Frontiers in pharmacology
2023

Inborn Errors of Metabolism Associated With Autism Among Children: A Multicenter Study from Iran.

Indian pediatrics
2023

Short Peptoid Evolved from the Key Hydrophobic Stretch of Amyloid-β42 Peptide Serves as a Potent Therapeutic Lead of Alzheimer's Disease.

ACS chemical neuroscience
2022

Amyotrophic Lateral Sclerosis-Associated Persistent Organic Pollutant cis-Chlordane Causes GABAA-Independent Toxicity to Motor Neurons, Providing Evidence toward an Environmental Component of Sporadic Amyotrophic Lateral Sclerosis.

ACS chemical neuroscience
2022

Rational Design of a Peptidomimetic Inhibitor of Gelsolin Amyloid Aggregation.

International journal of molecular sciences
2022

Observational and clinical evidence that plant-based nutrition reduces dietary acid load.

Journal of nutritional science
2023

Evaluation of critical factors in the preparation of saliva sample from healthy subjects for metabolomics.

Journal of pharmaceutical and biomedical analysis
2022

Paeoniae Radix Rubra can enhance fatty acid β-oxidation and alleviate gut microbiota disorder in α-naphthyl isothiocyanate induced cholestatic model rats.

Frontiers in pharmacology
2022

Dehydration is associated with production of organic osmolytes and predicts physical long-term symptoms after COVID-19: a multicenter cohort study.

Critical care (London, England)
2022

Expanded newborn screening for inherited metabolic disorders by tandem mass spectrometry in a northern Chinese population.

Frontiers in genetics
2022

Energy consumption and intestinal microbiome disorders of yellow catfish (Pelteobagrus fulvidraco) under cold stress.

Frontiers in physiology
2022

Case Report: Compound Heterozygous Variants of the MAN1B1 Gene in a Russian Patient with Rafiq Syndrome.

International journal of molecular sciences
2022

The Combined Escherichia coli Nissle 1917 and Tryptophan Treatment Modulates Immune and Metabolome Responses to Human Rotavirus Infection in a Human Infant Fecal Microbiota-Transplanted Malnourished Gnotobiotic Pig Model.

mSphere
2022

Late-onset cblC deficiency around puberty: a retrospective study of the clinical characteristics, diagnosis, and treatment.

Orphanet journal of rare diseases
2022

NMR-based metabolomic analysis of human plasma to examine the effect of exposure to persistent organic pollutants.

Chemosphere
2022

The Different Metabolic Responses of Resistant and Susceptible Wheats to Fusarium graminearum Inoculation.

Metabolites
2022

Aristolochic acid-induced nephropathy is attenuated in mice lacking the neutral amino acid transporter B0AT1 (Slc6a19).

American journal of physiology. Renal physiology
2022

Metabolomics: A New Approach in the Evaluation of Effects in Human Beings and Wildlife Associated with Environmental Exposition to POPs.

Toxics
2022

β-Glucosidases as dominant dose-dependent regulators of Oryza sativa L. in response to typical organic pollutant exposures.

Environmental pollution (Barking, Essex : 1987)
2023

Circulating metabolite biomarkers: a game changer in the human prostate cancer diagnosis.

Journal of cancer research and clinical oncology
2022

Mechanism of ferroptosis in hypertensive nephropathy.

Translational andrology and urology
2022

Aberrant methylmalonylation underlies methylmalonic acidemia and is attenuated by an engineered sirtuin.

Science translational medicine
2022

Structural insights into the HBV receptor and bile acid transporter NTCP.

Nature
2022

Review of neuropsychological outcomes in isolated methylmalonic acidemia: recommendations for assessing impact of treatments.

Metabolic brain disease
2022

Seventeen Ustilaginaceae High-Quality Genome Sequences Allow Phylogenomic Analysis and Provide Insights into Secondary Metabolite Synthesis.

Journal of fungi (Basel, Switzerland)
2022

The markers of the organic acidemias and their ratios in healthy neonates in Serbian population.

Drug metabolism and personalized therapy
2022

New Kids on the Block: Bile Salt Conjugates of Microbial Origin.

Metabolites
2021

Metabolomics in endometriosis: challenges and perspectives for future studies.

Reproduction &amp; fertility
2022

Calpain activation and progression of inflammatory cycles in Parkinson's disease.

Frontiers in bioscience (Landmark edition)
2022

Inborn error of metabolism patients after liver transplantation: Outcomes of 35 patients over 27 years in one pediatric quaternary hospital.

American journal of medical genetics. Part A
2022

Crystal structure of a putative short-chain dehydrogenase/reductase from Paraburkholderia xenovorans.

Acta crystallographica. Section F, Structural biology communications
2022

Creatine transporter-deficient rat model shows motor dysfunction, cerebellar alterations, and muscle creatine deficiency without muscle atrophy.

Journal of inherited metabolic disease
2021

Transient Insulin Resistance in Propionic Acidaemia: Knowing is half the battle.

Sultan Qaboos University medical journal
2021

Multiomics analysis of soybean meal induced marine fish enteritis in juvenile pearl gentian grouper, Epinephelus fuscoguttatus ♀ × Epinephelus lanceolatus ♂.

Scientific reports
2021

Towards risk stratification and prediction of disease severity and mortality in COVID-19: Next generation metabolomics for the measurement of host response to COVID-19 infection.

PloS one
2021

Structural determinants of ligands recognition by the human mitochondrial basic amino acids transporter SLC25A29. Insights from molecular dynamics simulations of the c-state.

Computational and structural biotechnology journal
2021

Clinical features and outcomes of patients with cblC type methylmalonic acidemia carrying gene c.609G>A mutation.

Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences
2021

CSF Metabolomics of Tuberculous Meningitis: A Review.

Metabolites
2021

SARS-CoV-2 promotes RIPK1 activation to facilitate viral propagation.

Cell research
2022

Metabolome-wide association study of serum exogenous chemical residues in a cohort with 5 major chronic diseases.

Environment international
2021

A Proton-Coupled Transport System for β-Hydroxy-β-Methylbutyrate (HMB) in Blood-Brain Barrier Endothelial Cell Line hCMEC/D3.

Nutrients
2021

Metabolomics in the Diagnosis and Prognosis of COVID-19.

Frontiers in genetics
2021

Reduced Expression of Slc Genes in the VTA and NAcc of Male Mice with Positive Fighting Experience.

Genes
2021

Comparison of Untargeted Metabolomic Profiling vs Traditional Metabolic Screening to Identify Inborn Errors of Metabolism.

JAMA network open
2021

[Liquid chromatography-mass spectrometry-based metabolomics study of the efficacy of Chinese medicine asthma-relieving decoction on respiratory syncytial virus infection].

Se pu = Chinese journal of chromatography
2021

Induction of anxiolytic, antidepressant and analgesic effects by Shiff base of (E)-3-(1H-imidazol-4-yl)-2-((2-oxoindolin-3-ylidene)amino)propanoic acid derivatives in diabetic rats.

Journal of diabetes and metabolic disorders
2021

The Relevance of Plant-Derived Se Compounds to Human Health in the SARS-CoV-2 (COVID-19) Pandemic Era.

Antioxidants (Basel, Switzerland)
2021

Late-onset methylmalonic acidemia and homocysteinemia.

Nutricion hospitalaria
2021

Decreased Expression of Ileal Thyroid Hormone Transporters in a Hypothyroid Patient: A Case Report.

Frontiers in endocrinology
2021

Prediction of Type 1 Diabetes at Birth: Cord Blood Metabolites vs Genetic Risk Score in the Norwegian Mother, Father, and Child Cohort.

The Journal of clinical endocrinology and metabolism
2021

Metabolomic Patterns of Septoria Canker Resistant and Susceptible Populus trichocarpa Genotypes 24 Hours Postinoculation.

Phytopathology
2021

1-13C-propionate breath testing as a surrogate endpoint to assess efficacy of liver-directed therapies in methylmalonic acidemia (MMA).

Genetics in medicine : official journal of the American College of Medical Genetics
2019

Megasphaera lornae sp. nov., Megasphaera hutchinsoni sp. nov., and Megasphaera vaginalis sp. nov.: novel bacteria isolated from the female genital tract.

International journal of systematic and evolutionary microbiology
2021

Autism: Screening of inborn errors of metabolism and unexpected results.

Autism research : official journal of the International Society for Autism Research
2021

Dual targeting of polyamine synthesis and uptake in diffuse intrinsic pontine gliomas.

Nature communications
2021

Metabolic responses of whiteleg shrimp to white spot syndrome virus (WSSV).

Journal of invertebrate pathology
2021

Molecular and biochemical investigations of inborn errors of metabolism-altered redox homeostasis in branched-chain amino acid disorders, organic acidurias, and homocystinuria.

Free radical research
2022

Glutamatergic System is Affected in Brain from an Hyperthermia-Induced Seizures Rat Model.

Cellular and molecular neurobiology
2021

Comprehensive metabolic profiling of Parkinson's disease by liquid chromatography-mass spectrometry.

Molecular neurodegeneration
2021

Pancreatic involvement in patients with inborn errors of metabolism.

Orphanet journal of rare diseases
2021

Association Between Kidney Clearance of Secretory Solutes and Cardiovascular Events: The Chronic Renal Insufficiency Cohort (CRIC) Study.

American journal of kidney diseases : the official journal of the National Kidney Foundation
2021

A rare mutation c.1663G > A (p.A555T) in the MMUT gene associated with mild clinical and biochemical phenotypes of methylmalonic acidemia in 30 Chinese patients.

Orphanet journal of rare diseases
2021

An integrated study of metabolomics and transcriptomics to reveal the anti-primary dysmenorrhea mechanism of Akebiae Fructus.

Journal of ethnopharmacology
2021

The Differential Metabolic Profiles Between Deltamethrin-Resistant and -Susceptible Strains of Aedes albopictus (Diptera: Culicidae) by 1H-NMR.

Journal of medical entomology
2020

Lipidomic profiling of chorionic villi in the placentas of women with chronic venous disease.

International journal of medical sciences
2020

Disrupted Mitochondrial and Metabolic Plasticity Underlie Comorbidity between Age-Related and Degenerative Disorders as Parkinson Disease and Type 2 Diabetes Mellitus.

Antioxidants (Basel, Switzerland)
2021

Transporter Activity Changes in Nonalcoholic Steatohepatitis: Assessment with Plasma Coproporphyrin I and III.

The Journal of pharmacology and experimental therapeutics
2020

Biochemical phenotype and its relationship to treatment in 16 individuals with PCCB c.1606A > G (p.Asn536Asp) variant propionic acidemia.

Molecular genetics and metabolism
2020

Liquid-Chromatographic Methods for Carboxylic Acids in Biological Samples.

Molecules (Basel, Switzerland)
2020

Glutaric acidemia type 1: Treatment and outcome of 168 patients over three decades.

Molecular genetics and metabolism
2020

Metabolomics analysis of bronchoalveolar lavage fluid samples in horses with naturally-occurring asthma and experimentally-induced airway inflammation.

Research in veterinary science
2021

Liver and/or kidney transplantation in amino and organic acid-related inborn errors of metabolism: An overview on European data.

Journal of inherited metabolic disease
2020

Discovery of a stable tripeptide targeting the N-domain of CRF1 receptor.

Amino acids
2020

Metabolic characteristics of large and small extracellular vesicles from pleural effusion reveal biomarker candidates for the diagnosis of tuberculosis and malignancy.

Journal of extracellular vesicles
2020

Gut Microbiota and Metabolome Alterations Associated with Parkinson's Disease.

mSystems
2020

Development of a Tau-Targeted Drug Delivery System Using a Multifunctional Nanoscale Metal-Organic Framework for Alzheimer's Disease Therapy.

ACS applied materials &amp; interfaces
2020

A Machine Learning Approach for the Automated Interpretation of Plasma Amino Acid Profiles.

Clinical chemistry
2020

Metabolome of canine and human saliva: a non-targeted metabolomics study.

Metabolomics : Official journal of the Metabolomic Society
2020

The Essential Role of Selenoproteins in the Resolution of Citrobacter rodentium-Induced Intestinal Inflammation.

Frontiers in nutrition
2020

Variable phenotypes and outcomes associated with the MMACHC c.609G>A homologous mutation: long term follow-up in a large cohort of cases.

Orphanet journal of rare diseases
2020

AGC2 (Citrin) Deficiency-From Recognition of the Disease till Construction of Therapeutic Procedures.

Biomolecules
2020

Measuring Interactions Between Tau and Aggregation Inducers with Single-Molecule Förster Resonance Energy Transfer.

Methods in molecular biology (Clifton, N.J.)
2020

Plasma methylcitric acid and its correlations with other disease biomarkers: The impact in the follow up of patients with propionic and methylmalonic acidemia.

Journal of inherited metabolic disease
2020

4-Methylpseudoproline analogues of cyclolinopeptide A: Synthesis, structural analysis and evaluation of their suppressive effects in selected immunological assays.

Peptides

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Doença do metabolismo dos aminoácidos ou proteínas.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Doença do metabolismo dos aminoácidos ou proteínas

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Ordenadas pelo número de sintomas em comum.

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Expert consensus on the combined screening of genes and biomarkers for neonatal diseases.
    World journal of pediatrics : WJP· 2026· PMID 41452423mais citado
  2. Integrated pathological assessment and multi-omics analysis of the effects of Pinellia ternata aqueous extract on lung and spleen dysfunction in a rat model of phlegm-dampness obstruction.
    Journal of ethnopharmacology· 2026· PMID 41765120mais citado
  3. Discovery of first-in-class melanostatin-based ago-allosteric modulators of the dopamine D2 receptors.
    Biomedicine &amp; pharmacotherapy = Biomedecine &amp; pharmacotherapie· 2026· PMID 41687543mais citado
  4. Ileal Bile Acid Transporter Inhibitors in Cholestasis: Potential for More Than Just Paediatrics?
    Liver international : official journal of the International Association for the Study of the Liver· 2026· PMID 41645895mais citado
  5. Targeting cholinesterases with steroid hormone derivatives: Insights from In Vitro assays and molecular modeling.
    The Journal of steroid biochemistry and molecular biology· 2026· PMID 41628836mais citado
  6. Endothelial responses to angiogenic modulators highlight metabolic mechanisms underlying vascular dysfunction in preeclampsia.
    Placenta· 2025· PMID 41061497recente
  7. Blood metabolome of cardiovascular disease, diabetic kidney disease, and diabetic retinopathy in type 2 diabetes patients: A systematic review and meta-analysis.
    Endocr Res· 2025· PMID 40835231recente
  8. Analytical workflow for comprehensive blood metabolomics analysis by GC-MS. Application to children with ventilator associated pneumonia.
    J Chromatogr A· 2025· PMID 40306089recente
  9. A review on bacteria-derived antioxidant metabolites: their production, purification, characterization, potential applications, and limitations.
    Arch Pharm Res· 2025· PMID 40208553recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:79062(Orphanet)
  2. MONDO:0019189(MONDO)
  3. GARD:18937(GARD (NIH))
  4. Variantes catalogadas(ClinVar)
  5. Busca completa no PubMed(PubMed)
  6. Q18558086(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Doença do metabolismo dos aminoácidos ou proteínas
Compêndio · Raras BR

Doença do metabolismo dos aminoácidos ou proteínas

ORPHA:79062 · MONDO:0019189
MedGen
UMLS
C0002514
Wikidata
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades

📋 Origem dos dados

Esta página agrega dados de fontes públicas e oficiais. Dados sobre cobertura no SUS (PCDT, CEAF) são verificados ativamente por agente proativo (ver badge no infobox). Demais dados têm atribuição de fonte + data da última sincronização — clique para abrir o original.

Doença rara (ontologia)
fonte: Orphanet
Identificador unificado
fonte: MONDO
Indexação biomédica
fonte: MeSH (NLM)
Dado público estruturado
fonte: Wikidata